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Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer with a 5-year overall 
survival (OS) rate of less than 10% among patients diagnosed with disseminated disease. During 
the past decade the emergence and use of novel targeted therapy and immunotherapy has 
significantly increased the 5-year OS rate (34%). There are some CMM patients who harbor 
primary resistance to current therapeutic regimes and hence never respond to treatment, whereas 
a major subset of the patients with objective response ultimately develops a refractory disease due 
to acquired resistance. Moreover, clinical biomarkers that can be used to find patient subgroups 
who are most likely to benefit from a particular therapy remains elusive.  
In paper I, we found that the combination treatment of ERBB family inhibitor afatinib and 
MET/ALK inhibitor crizotinib was cytotoxic to CMM cells independent of BRAF/NRAS mutation 
status. The observations were validated both in vitro and in vivo.  
In paper II, we explored the molecular mechanisms behind the combination treatment effect of 
afatinib and crizotinib. We found that the combination treatment downregulated IRS-1, RPS6KB1 
and RPS6 protein expression. PMEL/Melanoma gp-100 and PI3K-p85 were upregulated in cells 
with induced resistance to the combination. We also showed that the resistance to the combination 
was reversible after a drug holiday.  
In paper III, we found that the efficacy of MTH1 inhibitor TH1579 is independent of BRAF/NRAS 
mutation status. TH1579 abrogated cell growth both in vitro and in vivo. We showed that AXL 
and CAV-1 play a role in mediating sensitivity to TH1579. Moreover, combination treatment of 
BRAF inhibitors with TH1579 further potentiated cell death in BRAF mutant CMM cells, 
including BRAF inhibitor resistant CMM cells. 
In paper IV, we showed that co-expression of MTH1 and PMS2 mRNA, key players in the DNA 
damage response pathway, is associated with shorter progression free survival after 
immunotherapy in CMM. We also found that these proteins were increased in refractory tumors. 
Finally, we showed that co-silencing of MTH1 and PMS2 further induced apoptosis compared to 
silencing of either gene alone in patient-derived short-term CMM cell cultures. 
Overall this thesis highlights potential novel targeted therapeutic strategies for patients with CMM 
and suggests possible alternate molecular markers that can be targeted to overcome resistance 
mechanisms that currently pose as a serious clinical challenge in the systemic treatment of CMM. 
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Skin is the largest organ in the body and is involved in many vital functions like protecting 
the human body against excessive water loss, from physical, chemical or biological 
assailants, in regulating our body temperature. Additionally, it also serves as a metabolic sink 
for storage of energy in the hypodermis. The skin microenvironment is comprised of a 
dynamic complex of several cellular constituents, one of them being melanocytes- the 
pigment producing cells in our body that protect us from harmful UV-radiation (Nestle, Di 
Meglio et al. 2009).  Transformation and uncontrolled growth of melanocytes can give rise 
to malignant skin neoplasms. Cutaneous malignant melanoma (CMM) is the most aggressive 
form of skin cancer responsible for approximately 500 deaths annually in Sweden (Swedish 
melanoma registry). Globally, around 300,000 new cases with 61,000 deaths due to CMM 
were reported in 2018 (Pasquali, Hadjinicolaou et al. 2018). Although primary CMM can be 
cured with surgery, treatment of the disseminated disease is associated with poor prognosis 
due to intrinsic and acquired drug resistance (Somasundaram and Herlyn 2012). One of the 
most difficult therapeutic challenges in CMM is to overcome resistance to systemic therapies 
and thereby avoid disease progression. In the past 7 years several prospective randomized 
clinical Phase III trials have tested novel substances targeting the Mitogen Activated Protein 
Kinase (MAPK) pathway, potent mutant BRAF (around 50% CMM patients carry BRAF 
mutation) and MEK inhibitors in combination which have improved the clinical outcome 
with a median progression-free survival (PFS) of 21% at 4 years and 19% at 5 years. This 
combination has therefore been approved as first line treatment for CMM patients harboring 
unresectable or metastatic tumor with a BRAF V600E or V600K mutation (Robert, Grob et 
al. 2019). However, a majority relapse due to development of acquired drug resistance 
(Johnson and Sosman 2013). In addition, immunotherapy with check-point inhibitors has 
given long-term therapeutic efficacy but only for a subset of the CMM patients (Hegde, 
Karanikas et al. 2016, Kozar, Margue et al. 2019), thus making it essential to identify novel 
therapy regimes for CMM independent of BRAF and NRAS mutations status.  
 
1.1 Skin: The multitasking organ 
The skin forms a first major mechanical, dynamic, and physical barrier between our body 
and environmental insults. Through the production of melanin (a dark colored pigment), the 
skin shields us from harmful ultraviolet (UV) radiations from the sun. Skin naturally presents 
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itself as a model organ of choice to study the response of organisms to local and systemic 
injuries owing to its easy accessibility (Nestle, Di Meglio et al. 2009). The structure of the 
skin is a major contributing factor that helps it to perform these multiple roles. Histologically 
the skin can be divided into three layers- epidermis, dermis and hypodermis. 
 
Figure 1: Skin anatomy and effector cells. Adapted from (Nestle, Di Meglio et al. 2009) 
1.1.1 Epidermis 
The epidermis is ectodermally derived and constitutes the outermost layer of the skin. It is a 
non-vascularized squamous epithelial layer mostly comprising of keratinocytes and is 
stratified into four sub layers: Stratum corneum, stratum granulosum, stratum spinosum and 
stratum basale (Chamcheu, Roy et al. 2019). The epidermis is also home to other cell types 
like melanocytes, Langerhans cells and T-lymphocytes (Figure 1). Merkel cells which are 
oval shaped mechanoreceptors which aid us to discern shapes and textures and also light and 
touch, can also be found in the epidermis (Di Meglio, Perera et al. 2011). 
1.1.2 Dermis 
The next layer of the skin is the dermis. It is mesodermally derived, enriched in collagen and 
connective tissue. The collagen matrix acts as a physiological barrier and a structural 
framework for blood and lymphatic vessels. The dermis is also embedded by a complex 
milieu of different cell types like T cells, natural killer cells, mast cells, fibroblasts, 




The underlying layer of sebaceous tissue beneath the dermis is the hypodermis. It mainly 
constitutes of a meshwork of adipose tissue and blood vessels. The primary function of this 
layer is to store fat and maintain body temperature by heat insulation (Chamcheu, Roy et al. 
2019).   
 
1.2. Pathophysiology of melanoma 
Malignant transformation of cells producing pigment (melanocytes), occurring primarily in 
the skin, but also in other parts of the body like mucosal membranes of the head and neck 
area, GI tract, genital organs and eyes, is the cause of malignant melanoma. UV radiation is 
the major environmental risk factor for developing CMM. Exposure to UV radiation can 
cause photocarcinogenesis mainly attributed to formation of mutations at localization of 
incorrectly repaired DNA photoproducts, most commonly thymine dimers. Other factors that 
enhance the risk of developing CMM are specific genetic aberrations, age, male sex, 
phenotypic appearance (hair color, skin type), number of nevi (moles) and presence of 
abnormal dysplastic nevi (Schadendorf, Fisher et al. 2015). Recent studies have identified 
several pathways that are involved in the process of melanoma-genesis; the transformation 
of normal melanocytes into melanoma cells (Figure 2). CMM onset and progression can be 
broadly defined into four major steps: (1) Transformation from a benign nevus with limited 
growth to a premalignant dysplastic nevus with aberrant proliferation; (2) Radial growth 
phase (horizontal growth  and epidermal spreading; (3) Vertical growth phase (invasion 
vertically through basement membrane; (4) Metastasis (dispersal of melanoma cells to  
lymph nodes and other tissues) (Miller and Mihm 2006).  
 
Figure 2: Molecular changes associated with CMM onset and progression. Adapted from (Miller and 
Mihm 2006)   
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CMM can be broadly classified as chronically sun damaged (CSD) versus non-chronically 
sun damaged (non-CSD) melanoma depending on the extent of skin damage induced by the 
sun at the site of origin (Shain and Bastian 2016).  
High levels of reactive oxygen species (ROS) is known to cause DNA damage. Since both 
melanocytes and melanoma cells have elevated ROS, previous works suggest CMM to be to 
some extent a ROS driven tumor (Meyskens, Farmer et al. 2007, Wittgen and van Kempen 
2007, Das, Gad et al. 2020). Melanin, the pigment, has been identified as a melanocyte-
specific source of ROS and is synthesized, stored and transported in the melanosome 
organelle. Pheomelanin, one out of two forms of melanin, is known to produce ROS after 
exposure to UV irradiation. High levels of pheomelanin can thereby indirectly contribute to 
mutagenesis (Figure 3) (Shain and Bastian 2016). Elevated levels of ROS is a double-edged 
sword as, on one hand, high ROS levels may promote cell proliferation, metastasis and 
survival (Ishikawa, Takenaga et al. 2008), but on the other hand, elevated ROS levels may 
also cause DNA damage, inhibit tumor cell proliferation and induce cell death or cell growth 
arrest (Ramsey and Sharpless 2006, Das, Gad et al. 2020).  
 
 
Figure 3: UV/ROS induced abberant structural changes in pheomelanosome and eumelanosome 




1.3 DNA damage response 
Genomic instability has been featured as a cancer hallmark (Hanahan and Weinberg 2011). 
It is one of the most pervasive cancer characteristics which stems from a combination of 
DNA damage, deficits in cancer repair mechanisms, and an inability for cancer cells to repair 
these defects before the DNA is passed onto the daughter cells. DNA damage is thereby 
known to cause replication stress (Lans, Hoeijmakers et al. 2019). To faithfully maintain 
genomic stability, cells possess complex mechanisms which are broadly referred to as DNA 
damage response pathways (Lord and Ashworth 2012). Solar UV radiations are known to 
play a major part in DNA damage induction. They are mainly responsible for the induction 
of pyrimidine dimers which contain deamination prone cytosine, and if left unrepaired can 
cause cytosine residues to be replaced by thymidine. Ionizing radiations can also cause single 
strand or double strand breaks (SSB or DSB) in the DNA backbone which may give rise to 
mutations and cause structural rearrangements within the genome. Moreover, mutations 
developed after UV exposure caused by error prone DNA polymerases can be mediated by 
ROS. In order to maintain genomic stability, melanoma cells are armored to handle the 
deleterious effects of ROS in different ways. One of the ways is through up-regulation of 
ROS metabolizing enzymes including superoxide dismutases, SODs. Tumor mutation 
burden (TMB) which is a readout of the number of mutations within the tumor genome has 
been shown to be a promising biomarker for predicting response to immune checkpoint 
inhibitors (ICI) (Wu, Xu et al. 2019). Moreover, reports have shown that melanoma or non-
small cell lung cancer (NSCLC) patients with high TMB respond better to ICI than those 
with low TMB (Snyder, Makarov et al. 2014, Rizvi, Hellmann et al. 2015). Thus, genomic 
instability therefore paves avenues for therapeutic interventions for cancer treatment. 
Furthermore, a recent recommendation by the European Society of Medical Oncology 
(ESMO) highlights that microsatellite instability (MSI) in cancers deficient in mismatch 
repair (MMR) proteins, together with tumor burden and PD-1/PD-L1 expression can be 
collectively useful as predictive biomarkers for immunotherapy (Luchini, Bibeau et al. 2019). 
1.3.1 DNA damage response pathway 
Cells are equipped with a wide armory of DNA repair mechanisms to combat insults from 
external and endogenous agents that cause DNA damage. These DNA damage response 
pathways coordinate to recognize the DNA damage indicate the existence of the damage and 
finally mediate the repair. There exists five major DNA repair mechanisms: Base excision 
repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), homologous 




Figure 4: DNA damage and repair mechanisms. Adapted from (Dexheimer 2013). 
1.3.2 PMS1 protein homolog 2 (PMS2) 
PMS2 which is an important DNA repair protein in the MMR pathway dimerizes with 
MLH1. Patients carrying heterozygous PMS2 variants have been associated with increased 
risk of developing colorectal and endometrial cancers (Ten Broeke, van der Klift et al. 2018). 
Studies have shown that mutations in PMS2 promoter can be found in around 7.5% of CMM 
cases (101/1,348), which were associated with more than 5-fold higher tumor mutational 
burden when compared to tumors with wild-type PMS2 (Chalmers, Huang et al. 2016). Loss 
of PMS2 protein in primary CMM has previously been shown to be associated with higher 
Clark´s levels, but had limited prognostic significance (Korabiowska, Brinck et al. 2000). 
There has also been another study which has shown loss of PMS2 protein expression in CMM 
vs benign nevi (Alvino, Passarelli et al. 2014). 
1.3.3 MutT Homolog 1 (MTH1) 
Maintaining the genomic integrity by having optimal levels of ROS becomes an integral 
function of the tumor cells, which is why they often up-regulate several DNA repair 
mechanisms, one of them being MutT Homolog 1 (MTH1).   
Although tumor cells have increased MTH1expression, it is not essential for normal cells. 
MTH1 is a member of the Nudix hydrolase that sanitizes the dNTP pool by hydrolyzing 
harmful oxidative stress induced 8-oxo-dG, thus preventing its incorporation into DNA 
(Nakabeppu 2014, Nakabeppu, Ohta et al. 2017).  MTH1 protein has also been suggested to 
have a role during mitosis where it binds to tubulin, thereby ensuring correct spindle 
assembly, tubulin polymerization, mitosis progression and ablation of ROS generated during 
mitosis. In a recent study, it has been shown that MTH1 inhibitors (MTH1i) have a dual 
mechanism whereby it blocks mitosis, induce ROS generation and promote incorporation of 
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harmful 8-oxo-dG during mitotic phase (Warpman Berglund, Sanjiv et al. 2016). MTH1i 
mediates depolymerization of tubulin and causes cell growth to stall (cell cycle arrest) (Gad, 
Mortusewicz et al. 2019, Das, Gad et al. 2020). MTH1 has also been shown to cooperate with 
DNA glycosylases to promote survival of leukemia cells that are deficit in DNA repair 
enzymes (Eshtad, Mavajian et al. 2016). Previously published studies indicate that MTH1 is 
up-regulated in different carcinomas including colorectal cancer, glioblastoma and CMM 
(Koketsu, Watanabe et al. 2004, Pudelko, Rouhi et al. 2017, Wang, Liu et al. 2017). MTH1 
has also been suggested to play an important role in RAS driven tumors (Giribaldi, Munoz 
et al. 2015, Patel, Burton et al. 2015). A recent study showed that melanoma cells are 
protected by Skp2/MTH1 from induced oxidative stress upon MAPK pathway activation 
(Wang, Liu et al. 2017). It was also demonstrated that inhibition of MTH1 made melanoma 
cells more susceptible to apoptosis and that the expression levels of MTH1 was determined 
by Skp2 which is an S-phase associated protein kinase 2 (Wang, Liu et al. 2017).  
1.4 Protein phosphorylation 
Protein phosphorylation regulates a major portion of cellular life, abnormal levels of which 
can cause onset of disease. It is one of the most common post translational modifications 
(PTM). Proteins can be phosphorylated on serine (86.4%), threonine (11.8%) or tyrosine 
(1.8%) residues (Roskoski 2012). Protein phosphorylation is a vital process that regulates 
multitude of cellular processes like protein synthesis, cell growth and development, signal 
transduction, cell division and aging. These events occur via the activation and deactivation 
modulated by specific kinases and phosphatases (Schwartz and Murray 2011, Ardito, 
Giuliani et al. 2017).  
1.4.1 Kinases  
The protein kinase family carries out cellular phosphorylation events. Kinases are activated 
by phosphorylation which leads to a downstream cascade activation. About one-third of all 
proteins can be modified by kinase activity, thus regulating major pathways within the cell 
(Ardito, Giuliani et al. 2017). These modifications can alter the activity and localization of 
proteins. Protein kinases including receptor tyrosine kinase are being studied extensively 
since they have been implicated to be one of the most frequently mutated gene families 
associated with cancer pathogenesis (McDonell, Kernohan et al. 2015). 
1.5 Common aberrations in CMM 
1.5.1 The involvement of MAPK and PI3K pathways in melanoma development 
RAS/RAF/MEK/ERK (MAPK) pathway is frequently deregulated in a number of different 
cancer types including CMM. As with RAS family GTPases, mutant RAF proteins can also 
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play a role as drivers of human disease states like cancer.  This pathway controls several 
major cellular processes including cell proliferation, survival and differentiation. Alterations 
in the MAPK pathway are commonly associated with CMM. Based on the tumor genetic 
profiles, patients can be divided into three subclasses. Around 50-60% of CMM patients have 
primary tumors harboring an activating mutation in the BRAF gene (majority have BRAF 
V600E/K). BRAF V600E mutations are most common in melanomas found in intermittently 
sun exposed skin, whereas skin high UV exposure results in primary tumors with activating 
NRAS mutation (NRASQ61R, NRASQ61K, NRASQ61L, NRASG12D) (~30% of CMM 
patients), and BRAF non V600E mutations. The BRAF and NRAS mutations are to a high 
degree mutually exclusive. The third group of CMM patients has primary tumors that are 
WT for both BRAF and NRAS. It has been shown that BRAF V600E mutations, an activating 
mutation, dramatically increase the kinase activity (Holderfield, Deuker et al. 2014). 
Additionally, there have also been some mutations reported in BRAF which causes a 
reduction in kinase activity (lesser than WT protein) and these tumors eventually rely on C-
RAF for the transforming abilities (Freeman, Ritt et al. 2013). During normal states, RAF 
dimerization cause RAF kinase activation and subsequently activates MEK. However, in the 
event of a disease onset, MEK/ERK activation is triggered by (1) mutant RAF proteins 
harboring partial or completely impaired kinase activity, (2) RTKs or Ras GTPases that are 
activated due to a mutation, (3) homodimerization of V600E- BRAF splice variants that are 
also known to contribute to resistance to BRAF inhibitors (BRAFi) or (4) treatment with 
ATP-competitive RAF inhibitors in the presence of constitutively activated RAS (Figure 5) 
(Freeman, Ritt et al. 2013).  
 
Figure 5: RAF dimerization in cell signaling. Adapted from (Freeman, Ritt et al. 2013). 
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Driver oncogenes like BRAF and NRAS have also been found in nevi. Mutation in these 
oncogenes is associated with oncogene induced senescence (OIS) but this function is 
inactivated in melanoma cells. For example, it has been shown in human diploid fibroblasts, 
senescence like growth arrest is induced in both CDKN2A and RAS-RAF-MEK pathway 
(Brookes, Rowe et al. 2002). However, it has also been shown that CDKN2A deficiency in 
a BRAFV600E knock in mouse model reduced melanocyte senescence. Additional tumor 
suppressor altering changes like deletion in lipid phosphatase and tensin homolog (PTEN) 
and mutation in TP53 are associated with a rapid progression of melanocytic lesions (Peeper 
2011). PTEN deletion has been suggested to be a bypass mechanism for OIS during 
melanogenesis (Wagner and Gil 2018). Moreover, accumulation of P53 and CDKN2A has 
also been shown to contribute towards RAS mediated premature senescence induction 
(Serrano, Lin et al. 1997).According to the cbioportal database for CMM cases, mutations 
and putative copy number alterations in CDKN2A, TP53 and PTEN comprise of 43%, 17% 
and 15% respectively.  
CDKN2A is a common melanoma susceptibility gene encoding two different tumor 
suppressor proteins p16INK4A and p14ARF. The p16INK4A protein is an important gatekeeper 
of the G1/S check point, while the p14ARF protein stabilizes p53. p16INK4A binds to cyclin 
D1 and acts as a competitive inhibitor of CDK4. This complex keeps the tumor suppressor 
Retinoblastoma protein (RB) active and prevents cell cycle progression (Curtin, Fridlyand 
et al. 2005).  Frequency of genetic and epigenetic alterations affecting p16INK4A only is 
around 20%, whereas frequency of mutations affecting both p16INK4A and p14ARF is around 
40% (Rizos, Darmanian et al. 2001, McWilliams, Wieben et al. 2011). In a study to 
investigate the loss of p16INK4A, it has been shown that NRAS mutated melanoma have a high 
frequency of CDKN2A promoter methylation and in around 30% of the cases, protein 
expression was lost during progression from primary to metastatic tumor (Jonsson, 
Tuominen et al. 2010). 
Characterization of the whole genome of large patient cohorts with advanced melanoma has 
led to identification of other genetic alterations including inactivating mutations in NF1. 
NF1 is a negative regulator of RAS signaling pathway and patients with NF1 mutations have 
been categorized as another subset of CMM (Vogelstein, Papadopoulos et al. 2013). 
According to cbioportal, the proportion of melanoma tumors having genetic alterations in 
NF1 is around 13%. 
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Similar to the RAS/RAF pathway, the PI3K/AKT cascade also regulates several vital 
cellular processes like cell growth, cell proliferation, cell cycle and cell death and is 
aberrantly expressed in many different tumor types.  Some seminal studies have also 
highlighted that the PI3K/AKT pathway has multifaceted roles in melanoma pathogenesis, 
heterogeneity and resistance mechanisms. PI3K comprises of a dimer containing catalytic 
(p110) and regulatory (p85) subunits that can be activated by multiple signals, for example 
by RTKs, RAS/RAF pathway, physical cell-cell interactions (Figure 6). Once activated, the 
PI3K phosphorylates plasma membrane phosphatidylinositols at 3’-OH. This ensues 
activation of proteins containing domains with pleckstrin homology (PH) (including AKT) 
and attracts them to the cell membrane. AKT has three isoforms (AKT 1/2/3). The catalytic 
activity of AKT is then turned on by phosphorylation at two conserved residue, Thr 308 
(PDK1) and S473 (mTORC2). In turn, AKT phosphorylates and thereby activates a number 
of downstream effector proteins (including mTOR) which lead to a concomitant signaling 
cascade regulating several key cellular processes as mentioned before (Kwong and Davies 
2013).  PTEN which is a negative regulator of the pathway is mutated or deleted in 7.3% 
primary and 15.2 % metastatic CMM tumors (Agosto-Arroyo, Rosa et al. 2017). PTEN 
inactivates the PI3K/AKT pathway by converting phosphatidylinositol (3,4,5)- triphosphate 
(PIP3) back to phosphatidylinositol (4,5)- biphosphate (PIP2) (Dasari and Messersmith 
2010). Deletions in PTEN often, but not exclusively, co-occur with BRAF mutations. PTEN 
loss is correlated to shorter overall survival (OS) and elevated invasive disease capacity in 
CMM patients with tumors harboring BRAF V600E mutation (Bucheit, Chen et al. 2014). 
 
Figure 6: Schematic figure of MAPK/ERK and PI3K/AKT pathway activation. Adapted from (Dasari 




1.5.2 Receptor tyrosine kinases: crosstalk and role in CMM 
Receptor tyrosine kinases (RTKs) belong to a family of ligand-binding cell surface receptors 
that control different cellular functions. Currently there are 58 identified RTKs belonging to 
20 subfamilies, all harbouring the same basic structure comprising of an extracellular ligand 
binding domain, connected via a single pass transmembrane domain to an intracellular 
portion containing the main kinase active domain. In a normal state, canonical RTK activity 
is triggered by binding of their specific ligand resulting in receptor dimerization and 
conformational changes. Another subset of RTKs exists as oligomers which are then 
activated by ligand binding. Conformational changes as a result of ligand binding cause 
autophosphorylation of tyrosine residues, thus activating the RTKs (McDonell, Kernohan et 
al. 2015). 
Interactions between RTKs and PTPs result in aberrant growth and proliferation signalling 
that benefits the melanoma cell proliferation (Figure 7). RTK MET has been shown to be 
associated with melanoma survival, proliferation and invasion (Adachi, Sakai et al. 2016, 
Czyz 2018). Alterations in the expression levels of MET have been associated with changes 
in both growth and metastatic phenotypes. MET has been shown to play a pivotal role in 
melanoma metastasis to the lungs. It has been seen that inhibition of IGF1R signalling which 
led to the concomitant decrease in ERK signalling was able to induce cell death in melanoma 
cells with BRAFV600E mutation (Scurr, Pupo et al. 2010). Moreover, it has also been shown 
that AXL expression within the tumor microenvironment can contribute towards 
immunosuppressive and protumorigenic phenotypes in many cancer types including CMM 
(Rankin and Giaccia 2016). Data from the Oncomine database also demonstrated up to 5 fold 
increase in the mRNA expression of ERBB3 in melanoma when compared to normal skin 
(Easty, Gray et al. 2011), and has also been shown to contribute to metastatic transformation 
of melanoma cells (Tiwary, Preziosi et al. 2014). Crosstalk between different RTKs has also 
been studied in other cancer types where EGFR and ERBB2 act as key central hubs. ERBB3 
has been shown to promote cell survival by heterodimerizing with ERBB2, causing induction 
of signalling predominantly via the PI3K-AKT pathway (Zhang, Wong et al. 2013). It has 
been reported in a study on non-small cell lung cancer (NSCLC) that induction in the 
expression levels of EGFR is correlated with increased levels of IGF1R (Morgillo, Woo et 
al. 2006). To highlight the importance of receptor cross talk across different cancer types, a 
study has shown that in presence of HGF ligand, EGFR can bind to several cytoplasmic and 
transmembrane proteins thus possibly empowering cancer cells to utilize a broader range of 
12 
 
growth factors from the tumor microenvironment and ultimately leading to acquired 
resistance to targeted therapy (Gusenbauer, Vlaicu et al. 2013). 
 
Figure 7: Key molecular signaling pathways related to melanoma tumorigenesis. Adapted from 
(Luke, Flaherty et al. 2017).  
 
1.6 Systemic treatment in CMM 
1.6.1 Chemotherapeutics and targeted therapies 
Prior to 2011, standard of care for CMM patients with metastatic disease was mainly the 
chemotherapeutic agents dacarbazine or temozolomide, radiation therapy, with no 
discernable improvement in survival rates. However, the treatment landscape for CMM has 
been revolutionized since 2011 with the introduction of a number of systemic agents like 
BRAF inhibitors for patients with BRAF mutation and MEK inhibitors for blocking signaling 
via MAPK pathway. Monotherapy using BRAF or MEK inhibitor alone have resulted in 
clinical responses with limited duration in the BRAF mutant CMM patients, due to 
development of therapy resistance by reactivation of the MAPK pathway ultimately resulting 
in tumor recurrence (Villanueva, Vultur et al. 2011). A clinical trial designed to determine 5-
year survival rates of dabrafenib (BRAFi) plus trametinib (MEKi) in a cohort of 563 CMM 
patients with either unresectable or metastatic melanoma showed that PFS for combination 
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therapy was only 19% whereas OS was 34% at 5 years (Robert, Grob et al. 2019). Since an 
increased PFS and OS was observed with combination treatment as compared to single 
treatment, the current standard of targeted treatment employs the use of combination therapy.  
1.6.2 Immune checkpoint inhibitor therapy against CTLA-4 and PD-1 
Emergence of immunomodulatory drugs like anti-PD1 (programmed cell death 1) drugs 
(nivolumab, pembrolizumab) and anti-CTLA4 (cytotoxic T-lymphocyte associated protein 
4) drugs (ipilimumab) has transformed the landscape of melanoma treatment (Lugowska, 
Teterycz et al. 2018). The basic principle of immunotherapy accounts is blocking the 
interaction between the immune system of the patient and the surface molecules of the cancer 
cells. Immunotherapy aims to boost the anti-tumor immune responses in patients and thereby 
impede tumor growth and increase OS. Important players responsible for mediating immune 
responses against cancer are cytotoxic T-cells (CD8+). This requires activation of CD8+ T 
cells which is generally mediated by a two-step process: First, T cell receptor (TCR) mediated 
activation is triggered by a specific antigen on an antigen presenting cell (APC); second, by 
interaction between CD80/86 on APC and CD28 on the surface of the lymphocyte 
(Lugowska, Teterycz et al. 2018) (Figure 8). Proportion of CD8+ tumor infiltrating 
lymphocytes (TILs) have been associated with response to immunotherapy and has also been 
reported to increase during treatment in responders but in non-responders. Furthermore, 
CD8+ T cell localization at the tumor invasive margin has been attributed to increased 
immune response (Riaz, Havel et al. 2017). 
Figure 8: Immune checkpoint blockade. Adapted from (Havel, Chowell et al. 2019) 
CTLA-4 is a member of the immunoglobulin superfamily and is exclusively expressed on T-
cells. It is located mainly on intracellular vesicles and under healthy conditions, is only 
briefly expressed during activation before it is rapidly endocytosed. However, under disease 
conditions, CTLA-4 inhibits T-cell function and causes immunosuppression by binding to its 
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co-stimulatory molecule CD28 and thus quenching CD28 mediated signaling during antigen 
presentation. Removal of T-cell stimulatory receptors CD80 and CD86 from the cellular 
surface of APCs may also be orchestrated by CTLA-4, thus reducing their availability for 
other T-cells expressing CD28.  CTLA-4 has been shown to hamper immune responses 
against cancer cells. Blockade of CTLA-4 by anti-CTLA4 antibody abrogates its inhibitory 
effects, increases T-cell cytokine production which elevates T-cell expansion and tumor cell 
infiltration  (Domingues, Lopes et al. 2018, Seidel, Otsuka et al. 2018).   
Analogous to CD28, the cell surface receptor PD-1 is expressed on effector T cells, binds to 
its ligands PD-L1 and PD-L2 and ablates adaptive immune responses by inhibiting immune 
signaling. Studies have shown that by blocking TCR/CD28 mediated signaling and IL-2 
feedback loop, PD-1 dampens pro-survival signal, cell cycle progression and reduces 
cytokine production. Thus, blocking PD-1 using monoclonal antibodies inhibits binding of 
PD-1 to its ligands (Domingues, Lopes et al. 2018). 
A number of recent studies have shown that these checkpoint inhibitors have dramatically 
improved CMM patient survival. However, a strong difference was observed in number of 
durable responses (PFS) between CTLA-4 and PD-1 inhibitors. In a phase III clinical trial 
study when comparing anti-PD1 treatment (nivolumab) with anti-CTLA4 (ipilimumab) 
treatment, anti-PD1 was more effective than anti-CTLA4 (6.9 months vs 2.8 months median 
PFS). Recent data shows that 5 year OS rate in clinical trials for PD-1 inhibitor alone is 35-
40%. The study also shows that 4 year OS rate for nivolumab and ipilimumab in combination 
was more than 40% (Weiss, Wolchok et al. 2019).  Furthermore, another report indicates OS 
at 5 years in advanced treatment naïve CMM patients administered with ipilimumab and 
nivolumab in combination to be around 52% versus 44% for nivolumab and 26% for 
ipilimumab alone (Larkin, Chiarion-Sileni et al. 2019) .  
1.6.3 Targeted therapy and immunotherapy in combination 
Preclinical studies have shown that combining targeted therapy and immunotherapy 
alleviates anti-tumor immunity and could therefore be a good treatment strategy for CMM 
patients (Cooper, Juneja et al. 2014, Hu-Lieskovan, Mok et al. 2015, Deken, Gadiot et al. 
2016). Clinical trials designed to combine BRAF, MEK inhibitors together with 
immunotherapy seem to have some underlying benefits in terms of improved response rates, 
but with increased toxicity (Ribas, Puzanov et al. 2015). A clinical trial designed to combine 
ipilimumab (CTLA-4) with vemurafenib was terminated at a phase 1 trial due to patients 
developing dose limiting toxicities. Studies of combination therapy with BRAF/MEK 
inhibitors and PD-1/PD-L1 antibodies are ongoing (Simeone, Grimaldi et al. 2017, Clark, 
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Singh et al. 2018, Mooradian, Reuben et al. 2018). The response rates for these studies are 
variable depending on the sequence of drug administration. For example, a study where 
patients have first received targeted therapy after immunotherapy had a PFS of 5.6 months 
and an OS of 19.6 months, whereas those who progressed on targeted therapy and received 
anti-CTLA4 after had a much poorer response rate with PFS of 2.7 months and OS of 5 
months (Pelster and Amaria 2019). Together with targeted therapy and immunotherapy, 
cytotoxic chemotherapy, surgical resection and radiotherapy will continue to be treatment 
options for CMM patients. 
 
1.7 Mechanisms of therapy resistance  
1.7.1 Resistance to chemotherapy 
Treatment using chemotherapy has been ineffective for patients with metastatic melanoma, 
primarily due to development of intrinsic drug resistance. Both intrinsic and acquired 
resistance can be attributed to several factors, some of which are as follows: reduction in 
intracellular accumulation of chemotherapy drugs due to increased activity of drug efflux 
systems; diminished availability of free drugs to bind to intracellular targets due to 
inactivation of the drugs by altered enzyme activation; increased DNA repair activity thus 
impairing chemotherapy mediated cytotoxic effects; modulating the apoptotic pathway to 
increase pro-survival signals (Kalal, Upadhya et al. 2017). Other factors include 
accumulation of MITF, premelanosome gp100 (gp100/PMEL), MLANA (MART1) and 
melanosome trafficking related protein RAB27a (Chen, Leapman et al. 2009, Hertzman 
Johansson, Azimi et al. 2013). 
1.7.2 Resistance to targeted therapy 
Resistance evolved to targeted therapies have been described in tumors progressing on BRAF 
+ MEK inhibitors, with alterations in BRAF frequently found among these resistant tumors. 
Multiple factors giving rise to resistance to BRAF and MEK inhibitors have been described. 
Amplification of mutant BRAF has been shown to be one of the resistance mechanisms. 
Dimerization of aberrantly spliced BRAF V600E isoforms have also been shown to 
contribute to BRAF inhibitor mediated resistance in 13-30% of CMM tumors (Rizos, 
Menzies et al. 2014, Krepler, Xiao et al. 2016). Excessive BRAF dimerization and enhanced 
association to MEK has been elucidated to be partially responsible for the resistance onset 
(Vido, Le et al. 2018).   
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There have been several alternative mechanisms that have been associated with resistance to 
MAPK inhibitors in CMM. Overexpression of COT, downstream mutations in MEK1, AKT1, 
PI3K, loss of PTEN  and secondary activating mutations in NRAS have been demonstrated 
to be underlying resistance mechanisms (Eroglu and Ribas 2016),(Rizos, Menzies et al. 
2014).   Activation of alternate escape pathways like PI3K-AKT or the YAP pathway have 
also led to acquired therapy resistance. Tumors can escape cell death by increasing the 
expression of anti-apoptotic proteins. Higher Bcl-xL expression has been shown to decrease 
apoptosis via the YAP pathway (Frederick, Salas Fragomeni et al. 2014). A similar increase 
in the levels of anti-apoptotic protein Bcl2A1 was observed in BRAF mutant melanomas 
subjected to treatment with BRAF-MEK inhibitors, but MITF expression was restored. 
Bcl2A1 expression levels were associated with poor clinical response to BRAF inhibitors in 
CMM patients (Haq, Yokoyama et al. 2013). De-regulation of MITF expression has been 
associated with development of resistance towards targeted therapies (Kozar, Margue et al. 
2019). In tumors with low MITF expression, reactivation of pathways like the PI3K-AKT 
have been associated with overexpression of RTKs MET, EGFR, ERBB3, AXL, EPHA2, 
PDFGβ, IGF1R and FGFR. (Chan, Singh et al. 2017, Luke, Flaherty et al. 2017) (Figure 7).  
A study on metastatic melanoma further corroborated the importance of RTK signalling for 
development of drug resistance to MAPK inhibitors in CMM. This study demonstrated an 
inverse correlation between MITF and activated EGFR signalling, which led to vemurafenib 
resistance in patients with recurrent CMM (Ji, Erin Chen et al. 2015). This was observed 
consistently in both patient samples and melanoma cell lines. EGFR driven reactivation of 
MAPK pathway has also been observed in BRAF mutant colorectal cancers, and this has been 
proposed to contribute towards resistance to BRAF inhibitors (Corcoran, Ebi et al. 2012). 
Similarly, high EGFR expression was found in about 40% of the BRAF mutant tumors from 
patients who develop resistance towards BRAF or MEK inhibitors. This was associated with 
the suppression of SOX-10 which led to upregulation of TGFβ and ultimately increased 
expression of both EGFR and PDGFβ (Sun, Wang et al. 2014). Plausibly, this was associated 
with downregulated MITF, as SOX-10 is an upstream regulator of MITF. Increased levels of 
ERBB3 have been seen with a decrease in the expression levels of MITF, thus leading to 
hyper-activation of PI3K-AKT pathway and drug resistance (Alver, Lavelle et al. 2016). 
Alterations in the immune compartment of CMM patients administered with MAPKi have 
also been shown to play a part in mediating resistance to targeted therapy.  For example, it 
has been shown that patients progressing on targeted therapy have lower T-cell infiltration 
and subdued expression of melanoma differentiation antigens (MDA) in the tumor. Also, 
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samples collected from CMM patients during treatment on targeted therapy have shown 
higher PD-1 expression as compared to samples collected at progression in T-cells present in 
the tumor microenvironment (Pelster and Amaria 2019). Another study has also highlighted 
that prolonged treatment with BRAFi alone or combination of BRAFi +MEKi lead to lower 
CD8+ T cells activity (Pieper, Zaremba et al. 2018). 
1.7.3 Resistance to immunotherapy 
CMM tumors are generally considered as ‘hot tumors’ since they are composed of infiltrating 
T cells in abundance and also express tumor antigens, making them detectable to the immune 
system which creates a favorable microenvironment with regard to response to ICI 
(Lawrence, Stojanov et al. 2013, Maleki Vareki 2018).  However, there are subsets of patients 
with ‘cold tumors’ who are non-responsive to ICI (Rivera Vargas and Apetoh 2019). 
Additionally, although patients initially respond to ICI, in many cases patients become 
resistant to therapy and eventually relapse.  
Some factors contributing to innate resistance are constitutive expression of PD-L1 ligands 
on cancer cells caused by either amplification of the PD-L1 gene or aberrant activation of 
oncogenic pathways like c-Jun/STAT3 in CMM. Some mechanisms for acquired resistance 
involve inflammatory factors secreted into the tumor microenvironment during therapy. 
There have been several studies reporting the role of cytokine mediated over-expression of 
PD-L1 while others have  
highlighted the role of JAK/STAT and NFKB pathways as mediators of PD-L1 upregulation 
(Chen, Crabill et al. 2019). Some recent studies have proposed a few resistance mechanisms 
to immunotherapy.  For instance, it has been shown that ICIs mediate selection pressure by 
enriching clones of tumor cells that can escape immune recognition and deletion through 
novel pathways. A recent study showed that cells taken from a PD-1 inhibitor refractory 
CMM patient had acquired mutations which made them less vulnerable to T-cell mediating 
elimination by IFN-γ response (Zaretsky, Garcia-Diaz et al. 2016). Another study showed 
that treatment with CTLA-4 inhibitor caused upregulation of another inhibitory receptor on 
tumor infiltrating immune cells, in this case V-domain Ig suppressor of T cell activation 
(VISTA) (Gao, Ward et al. 2017). Another study has highlighted a novel mechanism of 
resistance to PD-1 inhibitors where it has been shown that administered anti-PD1 inhibitors 
in vivo were removed by tumor associated macrophages (TAMs) (Arlauckas, Garris et al. 
2017).  Another study published by Trujillo et al in 2019 highlighted an association of β-
catenin and PTEN loss to secondary resistance to immunotherapy in CMM (Trujillo, Luke et 
al. 2019).  
18 
 
1.8 Biomarkers in CMM 
Biomarkers are generally classified as being prognostic or predictive  (Figure 9) (Tarhini and 
Kudchadkar 2018). A prognostic biomarker by definition can provide an overall insight into 
the disease outcome of a patient, whereas a predictive biomarker gives an idea about the 
likelihood of therapeutic response of patient’s disease to treatment. The overarching aim by 
using biomarkers is to improve treatment outcome by using personalized medicine. Lactate 
dehydrogenase (LDH) levels and S100-B levels have been used routinely as prognostic 
markers to test for occurrence and recurrence of CMM. LDH has been included as a 
determinant in staging of patients with distant metastasis in the American Joint Committee 
on Cancer (AJCC) melanoma staging system. Elevated LDH levels are also indicative of 
shorter PFS and decreased response rates to therapy (Diem, Kasenda et al. 2016). Mostly 
BRAF mutation is the biomarker used for determining choice of therapy in CMM. 
Additionally NRAS mutation status has also been used as a biomarker (LoRusso, Schalper et 
al. 2019). In a phase III study, they have also found that mutation and deletion in  CDKN2A 
was significantly associated with poor PFS and OS in patients treated with  dabrafenib+ 
trametinib (inhibitors of MAPK signaling) (Flaherty, Davies et al. 2016). Furthermore, the 
coBRIM trial  studying the effects of vemurafenib single treatment vs vemurafenib and 
cobimetinib in combination identified two potential biomarkers where immune response 
gene clusters were associated with  complete response and keratinization genes were 
associated with resistance (Yan, Robert et al. 2016). 
 




Several parameters have been suggested as predictive biomarkers for checkpoint inhibiting 
therapies, such as high PD-L1 expression (in anti-PD1 therapy) specific human leukocyte 
antigen typing, overexpression of interferon-γ-inducible genes, presence of tumor infiltrating 
lymphocytes (CD4+/CD8+), expression of lymphocyte-activation gene 3 (LAG3), tumor 
mutational load, positivity for neoantigen expression, and the individual microbiome 
(Buchbinder and Flaherty 2016, Seidel, Otsuka et al. 2018).High microsatellite instability 
(MSI) and deficiency in DNA mismatch repair have also been validated as biomarkers of 
immunotherapy response in a number of different cancer types associated with poor 
prognosis after chemotherapy in colorectal cancer patients (Boyiadzis, Kirkwood et al. 2018).  
Circulating tumor DNA (CtDNA) has also been shown to be an attractive biomarker for ICI 
since a recent study has shown that CMM patients treated with anti-PD-1(alone or in 
combination with anti-CTLA4) had higher therapy response rate when they were negative 
for ctDNA either before or after treatment (Lee, Long et al. 2017). One more factor shown 
to be indicative of increased response to immunotherapy is increased expression of TGFβ in 
serum of CMM patients administered with anti-PD1 (Nonomura, Otsuka et al. 2016). 
Elevated Th1 and CTLA-4 gene expression levels are also considered good prognostic 
factors since they were found in responders to anti-PDL1 in many solid malignancies 
including CMM (Herbst, Baas et al. 2016).  
 
1.9 Targeting RTKs in melanoma 
The addition of RTK and AXL inhibitors could help to circumvent the resistance developed 
in BRAF/NRAS mutant melanomas with low MITF (Muller, Krijgsman et al. 2014). MET has 
been correlated to resistance to BRAF inhibitors (Adachi, Sakai et al. 2016). HGF, the ligand 
for MET, secreted from stromal cells in the tumor microenvironment has been shown to 
promote drug resistance (Beuret, Flori et al. 2007). A recent study indicated that selective 
inhibition of MET or PI3K isoforms may overcome the resistance to MEK   inhibitors in 
metastatic uveal melanoma cells (Cheng, Chua et al. 2017), possibly implying a similar 
potential in CMM therapy. Personalized preclinical trial studies have suggested the use of 
MET inhibitors as second line therapies with encorafenib in double combination or 
encorafenib and binimetinib in triple combination for BRAF inhibitor resistant melanomas 
(Krepler, Xiao et al. 2016).   
The RTK EPHA2 has also been associated with MAPKi drug resistance. A recent study 
elucidates that silencing FLI or CD13 leads to de-phosphorylation of EHPA2 causing arrest 
in proliferation or apoptosis in melanoma cells (Azimi, Tuominen et al. 2017). RTKs 
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belonging to the ERBB and insulin family have also been reported to be associated with 
emergence of drug resistance. For example, inhibition of signaling via EGFR or SRC family 
kinases has been shown to revert BRAFi resistance in CMM (Girotti, Pedersen et al. 2013). 
Co-targeting the ERBB pathway and MAPK pathway has been suggested to enhance clinical 
efficacy and prolong therapeutic response of MAPKi (Abel, Basile et al. 2013). Furthermore, 
therapeutic destruction of the insulin receptor substrates like IRS-1 and IRS-2 have been 
shown to downregulate signaling mediated by IGF1R which prevented resistance acquisition 
to BRAFi in CMM (Reuveni, Flashner-Abramson et al. 2013).  
 
1.10 Melanoma disease models 
Over the past decades, both murine models of melanoma as well as zebrafish models have 
been developed to better understand the complex tapestry of the disease including melanoma 
etiology, molecular and cellular mechanisms behind its pathogenesis, tumor 
microenvironment and resistance mechanisms. These studies have led to the development of 
therapies targeting several molecules that are currently being used in the clinics to treat CMM 
patients (Figure 9). Some of the molecular targets are also used as biomarkers for better 
patient stratification during treatment. Different kinds of murine models are currently 
available and each one presents its own unique advantage and disadvantage depending on 
the research question to be answered.  For example, murine models like cell-line xenograft 
models and patient derived xenograft models are two types which are able to mimic the 
complex and heterogeneous character of the disease, thereby providing us with the unique 
opportunity to better predict human tumor responses to therapeutic drugs (Saleh 2018). 
Additionally, these models are fairly simple to establish. Both genetically altered zebrafish 
and mice models are also currently being actively used in the field of melanoma for screening 
and selection of drugs for the development of personalized medicine for patients (Figure 10).  
Zebrafish which is the only vertebrate model which can be used as a powerful platform for 
large scale drug screens has been shown to efficiently recapitulate human diseases (Barriuso, 
Nagaraju et al. 2015). It has emerged as a robust animal model for pre-clinical testing of 
active drug compounds or drug regimes, thus providing an alternative platform instead of 
using mice models. Moreover, an orthotopic zebrafish model for glioblastoma has been 
described that can be used for high throughput screening of drugs to identify and profile novel 
therapies, a method which is very difficult to perform on murine models (Pudelko, Edwards 
et al. 2018). In this approach, thousands of zebrafish embryos can be transplanted with the 
cancer cells of interest, and these can then be robustly screened for drugs.  
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Even though zebrafish models are useful as an initial screen and understanding of the effect 
of the drug tested, murine models are eventually needed to obtain more in-depth 
understanding of the pharmacokinetic and pharmacodynamic properties of the drug. 
Particularly patient derived xenograft (PDX) models,  so called “avatars” (personalized 
model for one patient’s cancer  generated by engrafting tumor tissue from a patient into a 
mouse), are proposed to be a predictive method for success in the clinic. (Lunardi and 
Pandolfi 2015).Additionally, transgenic tumor models have also paved the way for drug 
development. Both model organisms represent a wide variety of use in cancer research 
including transplantation assays, single-cell functional assays, in vivo imaging studies and 
transgenesis (Barriuso, Nagaraju et al. 2015). 
 
Figure 10: Animal models in clinical studies. Adapted from (Barriuso, Nagaraju et al. 2015) 
Although both murine models and zebrafish models are currently being used extensively for 
research, each model has its limitations. For example, intradermally injected xenograft mouse 
models of melanoma can cause rapid tumor formation resulting in ulceration of mouse skin 
and thereby early termination of an experiment. Tail vein injection of cancer cells to mimic 
a ‘metastasis model’ although frequently used does not represent the patient scenario since 
this model skips the initial steps of metastasis from the primary tumor into blood or lymph 
vessels. Since established cell lines are significantly different from the originating cells, 
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xenograft models are often poor in predicting clinical outcome (Beaumont, Mohana-
Kumaran et al. 2013). Zebrafish as a model organism also has certain drawbacks. The 
genome of the fish has many duplicate genes making genetic manipulation difficult. 
However, this is currently being overcome with the development of clustered regularly 
interspaced short palindromic repeats (CRISPR) technology. It is difficult to give water 
insoluble drugs to zebrafish due to inherent toxicity of other carrier solvents (Zhao, Huang 
et al. 2015). Other challenges also include possible precipitation of drugs and drug 
permeability (Letrado, de Miguel et al. 2018). Furthermore, zebrafish are raised in water at 
33ºC which is substantially different from the human body temperature and the temperature 
at which cells are cultured (37ºC). This could cause the cancer cells to not grow well and 
give rise to tumors.  Currently zebrafish xenograft studies are mostly performed using 
zebrafish larvae which do not have an adaptive immune system and hence the role of the 





In this thesis we aimed to find novel potential targeted therapies that could be beneficial for 
treatment of CMM independent of BRAF/NRAS mutational status. 
The objectives of this research were: 
 Paper I: To investigate whether the combination of afatinib (ERBB family inhibitor) 
and crizotinib (MET/ALK inhibitor) could be a potential therapeutic strategy for 
CMM independent of BRAF/NRAS mutation status 
 Paper II: To explore the molecular mechanisms behind the broad cytotoxic effects 
of afatinib and crizotinib in combination in CMM 
 Paper III: To investigate the cytotoxic potential of MTH1 inhibitor TH1579 
(Karonudib) alone or in combination with MAPK targeting drugs in CMM 
 Paper IV: To elucidate the association between PMS2 and MTH1 expression to 










































Patient material was collected at Karolinska University Hospital as FFPE (from pathology 
archives) or fine needle aspirates (FNA) (for establishing short term cultures) or as core 
biopsies from CMM patients with stage III/IV disease. Most of these samples were obtained 
either prior to onset of targeted therapy by MAPKi or checkpoint inhibitors, or collected 
during treatment/ at progression. All clinical material was collected after informed consent 
from patient. The studies have been approved by regional ethics committee in Stockholm, 
Sweden and has been conducted according to the Declaration of Helsinki’s principles.  
Tissue Microarray (TMA) containing 50 clinical sample cores in duplicates was purchased 
from US Biomax (Me1002a) (https://www.biomax.us/tissue-arrays/Melanoma/ME1002a). 
This array also contained normal skin tissue.  
Tissue Microarray (TMA) containing 65 clinical samples in duplicates from CMM patients 
with advanced stage melanoma (Stage III/IV) were procured as gifts from Prof. Meenhard 
Herlyn, The Wistar Institute, Philadelphia,USA. The collection of these samples have been 
approved by the Institutional Review Board (IRB) and the study has been conducted 
according to the Declaration of Helsinki’s principles. 
 
Xenograft murine model 
A375 (BRAF V600E) melanoma cells (3.6x106) and growth factor reduced matrigel matrix 
(VWR) were mixed in a 1:1 ratio and subcutaneously injected in the flank of 6-week-old CB-
17/Icr-Prkdcscid/scid females (Janvier). Once tumors reached palpable size, the treatment was 
commenced. Measurements for tumor size were conducted by using calipers thrice weekly 
and tumor volume was calculated using the formula vol= (D x d2) x 0.52, where d is the 
smallest diameter and D is the largest diameter. The weight of the animal was also noted at 
these points. In the animal model, the following dosing regime was followed. Afatinib was 
used at 20mg/kg, crizotinib at 15mg/kg and the combination treatment was afatinib and 
crizotinib (20mg/kg + 15mg/kg). The animals were treated daily using oral gavage for 5 
consecutive days, followed by two days without drug administration and this schedule was 
repeated one more time. The animals were sacrificed 14 days after start of treatment. All 
animal experiments were approved by Stockholm’s Ethical Committee of Animal Research 




Zebrafish embryo transplantation, treatment and luciferase measurement 
All cells were processed one hour prior to transplantation into zebrafish embryos (Pudelko, 
Edwards et al. 2018). Briefly, immediately prior to transplantation, highly concentrated 
suspension of cells was filled into non-filament micro-capillaries (World Precision 
Instruments) and approximately 100 cells were injected into the blastula of zebrafish embryos 
at 2 h post fertilization (hpf) after which they were put in E3 medium and incubated at 33°C. 
The next day, successfully transplanted embryos were screened for, dechorionized using 
Pronase (Sigma) and distributed into 6-well plates (25 embryos/well) containing E3 media 
with HEPES. MTH1 inhibitor TH1579 (dissolved in DMSO to 10 mM) was added directly 
to the medium to a final concentration of 20 μM or 40 μM. For the control, DMSO was used. 
For combination experiments, the embryos were instead divided into four groups (DMSO 
control, vemurafenib (10µM), TH1579 (20µM) or combination). During treatment, embryos 
were incubated at 33°C until individual tumor size detection by luminescence measurement 
(Hidex Sense). Randomization was performed at the onset of the treatment without any 
blinding. 
 
Cell culture, treatments and transfections 
Melanoma cell lines A375 and SkMEl2 were purchased from American Type Culture 
Collection (ATCC). A375VR4 (vemurafenib) and A375PR1 (PLX4720) are resistant 
sublines of A375 (Azimi, Tuominen et al. 2017). ESTDAB cell lines were obtained from 
European Searchable Tumor Line Database and Cell Bank (ESTDAB). Pimary short term 
cultures were established from patient FNA samples as described previously(Das, Wilhelm 
et al. 2019). Patient derived cell lines ANRU and KADA were obtained as gifts from Prof. 
Rolf Kiessling, Karolinska Institutet, Sweden whereas deidentified patient derived lines 
1205-Lu, 1346 and 3918 were obatined fom Prof. Meenhard Herlyn, The Wistar Institute, 
USA. Melanoma cancer associated fibroblasts (CAF) were obtained as a gift from Prof.Erik 
Sahai, Francis Crick Institute, UK. All BRAF mutant cells were cultured in MEM (Themo 
Scientific, Sweden) with supplements, whereas all NRAS mutant and BRAF/NRAS WT cells 
were cultured in RPMI-1640 (Themo Scientific, Sweden) with supplements. Patient derived 
cells were cultured in RPMI-1640, whereas CAF cells were cultured in DMEM (Themo 
Scientific, Sweden) with 1% ITS (Themo Scientific, Sweden) and supplements. All cell lines 
were cultured in the aforementioned media except when experimental conditions required 
cell lines to be cultured in another media. In such a case, cells were condionally adapted to 
new culture media before start of experiments.  Flourescently labeled cells were generated 
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for both in vitro and in vivo experiments by transfecting CMM cell lines with lentiviral 
plasmids followed by antibiotic selection for 1 week. H2B cells for time lapse experiments 
were also generated by lentiviral transfection followed by 7 days of antibiotic selection. Cells 
overexpressing MTH1 or transfected with shMTH1 were also established in a similar manner  
(Das, Gad et al. 2020). All transfections were performed using Lipofectamine 2000 (Sigma-
Aldrich Chemie Gmbh, Munich, Germany) according to manufacturer’s protocol. All cell 
lines were tested with LookOut Mycoplasma PCR detection kit (Sigma Aldrich, Stockholm, 
Sweden) and confirmed to be mycoplasma free.  
Afatinib resistant, crizotinib resistant and combination resistant cell lines used in paper IV 
are sublines of A375. These cell lines were created as induced resistant lines, where A375 
cells were plated in 6 well plates and treated with IC50 concentrations of afatinib, crizotinib 
or the combination. Dead cells were washed away, media was replaced with fresh media 
containing drugs and cells were subjected to constant drug pressure until resistant cell clones 
that were resistant to IC50 values of the drugs emerged. These clones were expanded for 2 
months while keeping them under constant drug treatment.  
All drugs used in this thesis was dissolved in DMSO. For the in vitro treatment studies in 
paper I and II, for most experiments unless otherwise stated, afatinib (Selleckchem) was used 
at 2µM, crizotinib (Selleckchem) at 2µM and the combination at 2µM+2µM. DMSO 
(corresponding to the % of DMSO in the combination treatment) was used as control for all 
experiments. For paper III vemurafenib (Selleckchem) was used at 0.1µM- 0.5µM, 
dabrafenib (Selleckchem) at 10nM and trametinib at 3nM (Selleckchem). For most 
experiments in paper III and IV, MTH1 inhibitor TH1579 (developed by the Helleday group) 
was used at 0.9µM. 
 
Whole genome sequencing 
Allprep universal kit was used to extract DNA from cell lines. The DNA quantification was 
done using NanoDrop 2000 instrument. 100 ng was subjected to whole genome sequencing 
(WGS) using library build-up with the Nextera DNA library prep, Illumina platform and in-
house developed post-read filtering (Science for Life Laboratory, Stockholm, Sweden). 
Partek Flow software and DNA-Seq Toolkit for Partek Flow was used to map resulting reads, 






2D, 3D MTS assay and drug synergy 
Cell viability assay in both 2D and 3D (spheroid generated by hanging drop method) formats 
were performed. Briefly, 3000-4000 cells per well were plated overnight for 2D and 10,000 
cells per well were plated until spheres formed and matured (3D). They were then treated 
with drugs for 72 h and for 2D assay, cell viablity was read out as absorbance (490nM). For 
the 2D assay, MTS solution (Promega, Madison, WI, USA) was used and  for 3D assay MTS 
solution CellTiter 3D (Promega, Madison, WI, USA) was used. Cell lysis was done and 
luminescence was used as a read out.  
For drug synergy assays, 800-1000 cells/well was dispensed in 384-well plates using a D300 
digital dispenser (Hewlett-Packard, Tecan Trading AG, Switzerland). Drugs were dispensed 
in wells and cells were exposed for drugs for 72 h after which flourescence was measured. 
Drug synergy plots were created using FIMM Synergy Finder 
(https://synergyfinder.fimm.fi). For all experiments (Tecan Spark 10M, Tecan Trading AG, 
Switzerland) plate reader was used. 
 
RNA extraction  
 
AllPrep DNA/RNA/miRNA kit (Qiagen, Hilden, Germany) was used to extract RNA from 
cells. Agilent Bioanalyzer 2100 instrument (Agilent Technologies Inc., Santa Clara, CA, 
USA) was used to measure RNA quantity and quality. 
Real-Time PCR 
A 20 µl reaction using standard reagents from Invitrogen with SuperScript III reverse 
transcriptase (Calsbad, CA, USA) was prepared to convert the extracted RNA into cDNA 
which was further diluted and subjected to semi-quantitative real-time PCR reaction in a Bio-
Rad CFX instrument (Hercules, CA, USA). CFX Manager software was used to analyze the 
results.  
 
Extraction of data from targeted sequencing using Ion AmpliSeq ™ 
Targeted sequencing of fine needle aspirate or core biopsy RNA from metastases and RNA 
from cell lines was previously performed using the Ion AmpliSeq Transcriptome Human 
Gene Expression Kit for RefSeq genes ((Thermo Fisher Scientific, Waltham, MA. USA) as 
described in (Azimi, Tuominen et al. 2017).   
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Cell lysis for immunoblotting, RPPA and pRTK array 
RIPA lysis buffer containing phosphatase and protease inhibitors was used to lyse cells as 
previously described in (Das, Wilhelm et al. 2019).  For RPPA, lysates from cell lines and 
~50mg tumor tissue from xenografts was homogenized and processed in lysis buffer as per 
recommendation by the MD Anderson Cancer Center Functional Proteomics Core 
(MDACC) Facility. Standard protocols were used to denature protein lysates, followed by 
protein measurement estimation using BCA reagent (Thermo Fischer Scientific, Germany). 
Appropriate amounts of protein were used for western blot analysis, pRTK array (ARY001B) 
or for RPPA analysis conducted at the MDACC Functional Proteomics Core Facility. The 
data was analysed as previously described in (Davies, Stemke-Hale et al. 2009, Gopal, Deng 
et al. 2010).  
Immunoblotting and pRTK array 
40-50µg of denatured protein was loaded on 4-12% NuPage Bis-Tris gel (Thermo Fisher 
Scientific, Waltham, MA, USA). After completion of run, the proteins were transferred to 
PVDF membrane (GE Healthcare). Once the transfer process was complete, membranes were 
blocked with 5% milk or 5% BSA for 1h followed by overnight incubation in 4˚C with 
primary antibody. The following day, membranes were washed thrice with TBS-T and 
incubated with secondary antibody for another 1.5 h. Membranes were washed again and 
developed with ECL reagent (Thermo Scientific, Waltham, MA, USA) using Image Quant 
LAS 4000 (GE Healthcare Europe GmbH, Freiburg, Germany). For pRTK array, 150-200µg 
of protein was incubated with the appropriate array membranes (previously spotted with 
antibodies) overnight at 4˚C. The following day, similar steps were followed as mentioned 
above. Anti-HRP conjugated antibody as provided with the array kit was used as secondary 
antibody instead.  
Immunohistochemistry and immunocytochemistry 
Immunohistochemistry and immunocytochemistry were performed as per manufacturer’s 
protocol (Cell Signaling Technologies and Dako). Briefly paraffin embedded tissues sections 
or spheres were de-paraffinized and rehydrated. Antigen retrieval by either citrate buffer, 
proteinase K or EDTA was performed on sections followed by blocking in 3% hydrogen 
peroxide for 10 minutes and then in 2.5% horse serum for 30 minutes. Slides were incubated 
overnight with primary antibody against EGFR (1:50, Dako), ERBB3 (1:250, Cell Signaling 
Technologies), MET (1:300, Cell Signaling Technologies), Ki67 (1:400, Cell Signaling 
Technologies) or p-H2AX (1:200, Cell Signaling Technologies). Next day, sections stained 
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with ERBB3 and MET were incubated with rabbit signal stain boost (Vectastain art. 8114, 
Histolab Products AB, Stockholm, Sweden). For the sections stained with EGFR, ABC 
staining kit (Thermo Fischer Scientific, 32052) was used. DAB staining followed by 
counterstaining with haematoxylin was performed for all stainings followed by dehydration 
step. Slides were then mounted using Pertex (Histolab Products AB, Stockholm, Sweden) 
and imaged using Olympus Provis microscope. 
Independent evaluation of all slides was performed by three observers. The intensity 
(negative, low (1+), moderate (2+) or strong (3+)) and proportion of ERBB3, EGFR, MET, 
Ki67 and p-H2AX positive tumor cells was evaluated.  
 
Immunofluorescence 
Zebrafish embryos were processed to make cryo sections as previously described (Inoue and 
Wittbrodt 2011) and where then placed on glass slides. Slides were equilibrated with 3 
washes, 5 min each using 1X PBS-Tween 20. After this, they were blocked for 1 h at room 
temperature with 10 % goat serum (ab 7481) or donkey serum (ab 7475) in 1X PBS-Tween 
20. The slides were incubated overnight at 4 ˚C with either anti-CAV1 (1:400) or anti-AXL 
(1:100). Next day, the slides were washed with low shaking (50 rpm). They were incubated 
with secondary antibody (1:500) for 2 h, washed with 1X PBS-Tween 20 for 3 times, 5 min 
each. The slides were then mounted using DAPI fluoroshield (F6057) and imaged by 
AxioImager M2 (Zeiss). 
FFPE clinical and xenograft samples were deparaffinized and dehydrated in ethanol as per 
manufacturer’s protocol. Antigen retrieval was performed using citrate buffer (pH 6.0) 
followed by blocking with H2O2 and serum. Sections were incubated overnight with mTOR 
(1:75, Cell Signaling Technologies), MET (1:200, R & D Biosystems), RPS6KB1 (1:100, 
Sigma- Aldrich), pRPS6KB1 (1:100, Thermo Scientific), pRPS6 and RPS6 (1:200, Cell 
Signaling Technologies), ACSS1 (1:150, Santa Cruz Biotechnology), MTH1 (1:100, Novus 
Biologics) or PMS2 (1:100, BD Biosciences). The following day, sections were washed, 
incubated with secondary antibodies (1:200, rabbit Alexa Flor 488 or mouse Alexa Flor 594, 
Cell Signaling Technologies) for 2 h, and mounted with DAPI (Sigma Aldrich), visualized 
and imaged using AxioImager M2 (Zeiss). 




In-situ Proximity Ligation Assay (isPLA)  
isPLA experiments were performed by the PLA proteomics facility, Science for Life 
laboratory, Sweden. Briefly Duolink in situ PLA Sigma Aldrich (according to manufacturer’s 
protocol) were used to perform isPLA. Briefly, 0.5% Triton X-100 was used to permeabilize 
cells followed by TBST (TBS +0.05% Tween-20) wash and overnight blocking. Cells were 
incubated overnight with primary antibody and the following day, cells were stained with 
phalloidin (1:40) for 15 min at room temperature and mounted in media containing DAPI.   
Cells were then imaged using fluorescence microscope (Zeiss) and subsequently the PLA 
signal was measured using cell profiler software. 
 
Co-immunoprecipitation assay 
Cells plated at 85 % confluency were allowed to grow overnight. The following day, protein 
extraction was performed using these cells on ice using cell lysis buffer (cell signaling, 
#9803) with protease and phosphatase inhibitors and protein amount was quantified using 
BCA as previously described. Pre-washed magnetic beads (Thermo Scientific, #88802)   and 
primary antibody (concentration used as per manufacturer’s recommendation) were mixed 
with 300µg of protein and incubated overnight at 4 ˚C. Next day, unbound antibody from 
beads were washed away, beads were then boiled with 4X SDS (Thermo Scientific, # 
NP0007) to release the bound fraction and thereafter were the beads spun down. Supernatant 
was collected and analyzed using western blot. 
In vitro kinase assay 
Test compounds were nano-dispensed in 384-well, white, low volume, non-binding plates 
(Costar #3824). The AXL kinase reaction (V3961, Promega) was performed according to 
manufacturer’s protocol. Luminescence was recorded in Hidex Sense reader. 
 
CETSA- western blot 
CETSA (Cellular Thermal Shift Assay (CETSA) was performed as previously described in 
(Warpman Berglund, Sanjiv et al. 2016). Briefly, cells were plated to 70 % confluency.  The 
next day, cells were treated with DMSO or TH1579 (0.9 µM) for 2 h at 37 ˚C. They were 
then trypsinized and resuspended in media. Around 80 µl of cell suspension was added to a 
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PCR tube per heating condition and treated for 3 min (Veriti 96 well thermal cycler, AB). 
Samples were then lysed in RIPA buffer and analyzed by western blot. 
 
Cell confluency  
In 96 well plates approximately 2-3x 104 CMM cells were seeded and cultured with or 
without CAF conditioned media. Cell confluency was measured at 0 h, 6 h, 24 h and 48 using 
Tecan Spark 10M (Tecan Trading AG, Switzerland). For another experimental setup, CMM 
cells fluorescently labeled with eGFP were grown with or without unlabeled CAF cells for 
48 h or 14 days and treated with 1µM afatinib, 1µM crizotinib or the 1µM +1µM 
combination. eGFP signal was measured as a readout for CMM cell growth at similar time 
points after treatment as mentioned above. All readings in this experimental condition were 
normalized to DMSO.  
Cell Lysis for proteomic analysis  
Harvested cell pellets were resuspended in lysis buffer supplemented with phosphatase 
inhibitor (Roche Applied Science)). Cells were sonicated and centrifuged and protein 
concentration was determined as mentioned before using BCA reagent kit (Pierce). The 
protein lysates were reduced, enzymatically digested and the proteome and phosphoproteome 
were analysed using a label free method.   
Phosphoproteomics analysis 
200 μg of tryptic digest per sample underwent TiO2 phosphopeptide enrichment step as 
previously described (Azimi, Caramuta et al. 2018); and analysed by LC-MS/MS using a 
Fusion OrbiTrap (Thermo Fisher, Germany). The mass spectrometer was connected to a 
Dionex UHPLC system (Thermo Fisher Scientific, Germany).  
LC-MS/MS analyses 
The proteome and phosphoproteome of each sample were analyzed on a Fusion Orbitrap 
(Thermo Fisher, Germany) as previously described in (Azimi, Caramuta et al. 2018).  
Proteomic and phosphoproteomic data analyses 
The raw data were analyzed using MaxQuant 1.5.3.30 (Cox and Mann 2008) and Andromeda 
(Cox, Neuhauser et al. 2011)  was used to search the MS/MS data against the UniProt Homo 
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sapiens database (containing canonical and isoforms_42259 entries downloaded on 15th 
January 2018) complemented with a list of common contaminants, and concatenated with 
the reversed version of all sequences as previously described in (Azimi, Caramuta et al. 
2018). Data analysis was executed using Perseus (1.6.1.2). Only total 
protein/phosphopeptides with expression levels >1.5-fold changes (p<0.05) were considered 
for further analyses.  
Cell cycle analysis 
100,000 cells/well were plated overnight in 12 well plates, followed by treatment with either 
DMSO or 0.9µM TH1579 for 24h. The cells were trypsinized, collected and fixed using 4% 
buffered formaldehyde at room temperature, followed by fixation in 95% ethanol for 1 h, and 
rehydrated in distilled water for 1 h. Cells were treated with subtilisin Carlsberg solution 
containing protease (Sigma), stained with DAPI and analyzed using a LSRII flow cytometer 
(Becton Dickinson). DAPI fluorescence was measured above 435 nm. For histogram 
analysis, the ModFit program for cell cycle analysis (Verity software house) was used. The 
number of nuclei/histogram was 10 000. 
 
ROS measurement 
50000 cells/well were plated overnight in 12 well plates. For ROS measurements, cells were 
treated with DMSO, TH1579 (0.5µM or 0.9µM) or vemurafenib (0.45µM) or the 
combination for 3 h, trypsinzed, stained with CM-H2DCF (Life Technologies, C8627) and 
analyzed by FACS as per manufacturer’s protocol.  
Modified Comet assay 
Approximately 150,000-200,000 cells/well was seeded in 6-well plates followed by 
treatment with TH1579 or DMSO for 24 h on the next day. The modified comet assay was 
performed as earlier described (Gad et al. 2013). Briefly, cells were trypsinized, washed and 
resuspended in 1 x PBS at a concentration of approximately 1 million cells/ml. The cell 
suspension was mixed with low melting agarose, followed by the addition of the mixture in 
agarose coated slides. The slides were incubated in lysis buffer followed by three washes 
with enzyme buffer. OGG1 enzyme was added and slides were incubated for 45 min at 37°C. 
After this, alkaline denaturation with alkali buffer was carried out in an electrophoresis 
chamber for 20 min. Electrophoresis was run at 25 V and 300 mA in the same buffer for 30 
34 
 
min. The slides were later neutralized with neutralizing buffer for 45 min. The slides were 
stained with 1x SYBR gold dye immediately prior to imaging. 100 comets were counted 
using Comet IV software. 
Time-lapse microscopy 
In a 96 well black plate with transparent bottom 700-1200 cells/well were plated either in co-
culture or single, treated with DMSO or vemurafenib (0.4µM) or trametinib (3nM) or 
TH1579 (0.45µM, 0.9µM, 1.8µM) and incubated in 95 % humidified atmosphere with 5 % 
CO2 at 37°C. The plates were imaged between days 0-4 at intervals of 24 h with 10X using 
time lapse microscopy (ImageXpress MicroXL (Molecular Devises)). Cell profiler analyst 
software was used to quantify images.  
Flow Cytometry 
About 50000 cells/well were plated in 12 well plates overnight. The next day, cells were 
treated for 48 h or 72 h, followed by trypsinization and collection. Pellets were washed once 
with 1X PBS, the cells were resuspended in FACS buffer and then stained for 10 minutes in 
the dark on ice with 2% Annexin V and 2% PI solution (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany). After staining, an additional 200 µL FACS incubation buffer was added 
and analysis was performed using Novocyte 3000 and Novoexpress software (ACEA 
Biosciences, San Diego, CA, USA) to determine induction of apoptosis and necrosis.  
Scratch Assay 
In 3.5cm dishes, cells were plated at 90% confluency. With the help of a 100µL filter tip, a 
wound was created. Following this, cells were washed gently once with PBS and were 
exposed to DMSO, afatinib or crizotinib alone or in combination for 5 days. Cells were 
washed and the gap filling/wound healing was documented using picture documentation 
Nikon Eclipse TS-100 microscope after 0 h, 6 h, 24 h, 48 h and 120 h treatment. Analysis of 
the gap filling/wound healing was performed using ImageJ software. 
Transwell migration assay 
Approximately 3-5 X 104 cells were plated on inserts (CLS3422-48EA) containing media 
supplemented with 2% FBS and drugs or DMSO. The lower well was filled with 750µL of 
media containing 7.5% FBS (used as an attractant) and cells were allowed to migrate for 16-
24 h. The wells were then washed with PBS, fixed in 4% formaldehyde for 5 min followed 
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by 20 min in methanol. Cells were stained using crystal violet (Sigma), and imaged using 
Olympus Provis microscope. The crystal violet was dissolved in methanol and absorbance 
was measured at 540 nm using Tecan Spark 10M plate reader instrument. The readout was 
the number of migrated cells. 
Colony Formation Assay 
200-500 cells/well were plated in 6 well plates overnight ensued by treatment with either 
single or combination treatment for 5 days. After this media was replaced with regular media 
without drugs and colonies were allowed to mature for an additional 7 days, with the media 
being replaced every 3rd day. After this, colonies were fixed for 20 min using 4% buffered 
formaldehyde followed by staining with 0.05% crystal violet solution. The colonies were 
washed twice with 1X PBS to remove the extra stain, scanned using Epson scanner V370. 
To estimate amount of colony formation, crystal violet was dissolved in 100% methanol. In 
a 96 well plate, the crystal violet was diluted in 1:10 and absorbance was measured at 540 
nm using Tecan Spark 10M plate reader instrument. 
3D Invasion Assay 
Each well of an 8-chamber slide was coated with ten µL of 100% Matrigel (Sigma-Aldrich 
Chemie Gmbh, Munich, Germany). A cell suspension containing 15000 cells/mL and 4% 
Matrigel was added on top of the first coating and spheres were allowed to mature for 6 days. 
The media was replaced with media containing DMSO, afatinib or crizotinib alone or in 
combination for 72 h after which wells containing spheres were washed, fixed in 4% 
formaldehyde followed by washing and permeabilization with Triton X-100 for 15 min. 
Slides were blocked with 5% horse serum for 1 h and incubated for 1.5 h with Texas Red X 
Phalloidin (Thermo Fisher Scientific, Waltham, MA, USA). Slides were washed thrice with 
1X PBS, mounted with Fluoroshield containing DAPI (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany) and imaged using Zeiss AxioImager M2 microscope. 
Transmission Electron Microscopy 
Transmission electron microscopy (TEM) was performed using standard procedures of 
glutaraldehyde fixation and cell scraping prior to embedding for TEM. With a focus on the 
cell periphery, to study and compare presence of autophagosomes in cells treated with 









































4. RESULTS AND DISCUSSION 
 
4.1 Paper I: Combining ERBB family and MET inhibitors is an effective therapeutic 
strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation 
status 
 
Current clinically used MAPK targeting therapies for patients with disseminated CMM 
improve survival, but attaining a long-term clinical response is often challenging since in 
most cases, patients develop resistance to ongoing treatment and hence the disease relapses. 
A number of studies have highlighted the role of several RTKs in mediating resistance 
towards MAPKi. In this study, we investigated the therapeutic potential of combining MET 
and ERBB family inhibitors in CMM. 
 
4.1.1 Results: In this study, we show that MET and ERBB3 is highly expressed in patients 
with metastatic CMM (Paper I, Figure 1a) (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013). 
Moreover, transcriptional profiling of matched cases (sampled before treatment and at 
progression)  from two patients treated with MAPKi showed an increased mRNA expression 
of MET and EGFR/ERBB3 at relapse. Moreover, silencing of MET in BRAFi resistant 
A375VR4 cells caused an upregulation of EGFR, thus indicating RTK crosstalk (Paper I, 
Figure 1b-f). We therefore assessed the potency of afatinib and crizotinib as single treatment 
and in combination using cell viability as a readout. Using a panel of ten CMM cell lines (2D 
assay) and thirteen CMM cell lines (3D spheroid assays) with different BRAF/NRAS mutation 
status, we show that the combination treatment induced a significant (p<0.01) loss in cell 
viability as compared to DMSO or single treatments across all cell lines tested (Figure 11, 
Paper I, Figure 2, Supplementary Figure S4-S5). Dose response curves indicated that this 
combination treatment effect was synergistic (Paper I, Supplementary Figure S3). 
For further functional analysis, we chose five cell lines (A375, A375VR4, SkMel2, 
ESTDAB102 and ESTDAB105). To assess the effects on cell proliferation and cell death, 
we performed colony formation and FACS assays. We were able to show that the 
combination treatment abrogated cell proliferation (p<0.001) and induced cell death via 
apoptosis (p<0.05) (Paper I,Figure 3) when compared to DMSO or single treatments. We 
validated our findings using spheroids created from CMM cells where we treated the spheres 
for 72 h with DMSO, single or combination treatments and stained them with Ki67 and p-
H2AX to evaluate the effect on proliferation and DNA damage induction (Paper I, Figure 
4a-b, Supplementary Figure S6). Combination treatment was able to reduce proliferation 
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marker Ki67 and induce DNA damage marker p-H2AX more robustly when compared to 
single treatments or DMSO. 
 
Figure 11: (a) 2D MTS assay showing single and combination treatment effects on cell viability in 
CMM cell lines. (b) 3D MTS assay showing single and combination treatment effects on cell viability 
for spheroid models generated from established and short-term patient derived cell lines.(Das, 




Furthermore, using a spheroid model, we were able to show that the combination treatment 
was able to significantly reduce invasive capacity of CMM cells  over the single treatments 
and control (Paper I, Figure 4e). To test the effects on migration, we demonstrated using 
both a scratch assay and a transwell migration assay that the combination treatment 
significantly (p<0.01) attenuated CMM migratory capacity (Paper I, Figure 4f-g, 
Supplementary Figure S8). Using an in vivo A375 xenograft model, we showed that the 
combination treatment significantly caused tumors to grow at a slower rate whilst causing a 
significant (p<0.01) induction of p-H2AX and a reduction in Ki67 (Figure 12, Paper I, 
Figure 5, Supplementary Figure S9). These observations were more pronounced for the 
combination treatment compared to the other treatment arms.  
 
 
Figure 12: (a) Experimental design. (b-c) Tumor fold change and % increase in tumor volume after 
treatment. (d). Weight of animal recorded prior to start of treatment and at the end of treatment. (f-
g) Tumor tissues showing Ki67 staining as images and quantification of Ki67 positive foci. (h-i) 
Tumor tissues showing H2AX staining as images and quantification of H2AX positive foci.(Das, 




Lastly, we showed that dynamic molecular rewiring occurred when comparing culturing cells 
in 2D or as spheroids, here reflected by the changes in protein expression patterns of different 
RTKs (ERBB3, AXL, MET) and their downstream effectors (AKT) (Paper I,Figure 6b-c).  
 
4.1.2 Discussion: As per our knowledge, this is the first study on CMM demonstrating the 
broad cytotoxic effects of combining afatinib and crizotinib, clinically approved drugs for 
lung cancer treatment. Here we show that in BRAF mutant inhibitor sensitive cells and NRAS 
mutant cells, loss of WEE1 expression may contribute towards the combination mediated 
effects, whereas in BRAF mutant, inhibitor resistant cells and BRAF/NRAS WT cells, the 






Figure 13: Schematic of proposed mechanism of action of afatinib and crizotinib combination therapy 
 
 
Several studies have shown that in cancer, crosstalk between RTKs and other signaling 
pathways play an improtant contribution towards cancer intitiation, progression and drug 
resistance (Yamaguchi, Chang et al. 2014, Chan, Singh et al. 2017) . In this study we found 
evidence of crosstalk between MET and EGFR since downregulation of MET caused an 
upregulation of EGFR and AKT signaling in A375VR4 cells (Paper I, Figure 1f). It has also 
been shown that a crosstalk between ERBB3 and MET regulates invadopodia formation in 
melanoma cells (Revach, Sandler et al. 2019). Therefore, in this study, we employed the use 
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of a combination strategy to inhibit both ERBB family and MET concomitantly. One of the 
common resistance mechanisms towards EGFR/ERBB2 inhibitors is upregulation or 
activation of other RTKs, for example in non-small cell lung cancer (NSCLC), upregulation 
of AXL and amplification of MET and ERBB2 have been shown to contribute towards EGFR 
inhbitor resistance (Zhang, Lee et al. 2012). Moreover, in colon cancer, amplification of 
MET, ERBB2 and IGF1R has been shown to cause resistance to the EGFR inhibitor 
cetuximab (Bean, Brennan et al. 2007). The broad phenotypic effects of afatinib and 
crizotinib combination therapy can be attributed to the inhibiton of multiple targets, thus 
preventing plausible upregulation through RTK mediated crosstalk.  
The importance of WEE1 and IGF1R in contributing towards melanoma pathogenesis has 
also been described before. A recent study suggests that inhibiton of WEE1 contributed 
towards potent inhibiton of AKT3 which has been shown to be an important therapeutic  
target in CMM, but AKT3 does not have much effect when targeted alone (Kuzu, Gowda et 
al. 2018). Additionally, high expression of WEE1 has also been associated with poor disease 
free survival (DFS) in CMM (Magnussen, Holm et al. 2012) which is in accordance with our 
observation in this study where we have also shown a trend that CMM patients (n=17) with 
high WEE1 expression have lower PFS after immunotherapy (Paper I, Figure 6g). 
Suppression of IGF1R has also been shown to abrogate melanoma growth and induce 
apoptosis in melanoma cells (Xin, Lei et al. 2018). In this study, we also observed that IGF1R 
is downregulated in BRAF mutant inhibitor resistant cells and in BRAF/NRAS WT cells after 
combination treatment (Figure 13, Paper I, Figure 6k). Furthermore, we found that patients 
with high IGF1R expression have a shorter PFS after immunotherapy, although not 
significant (Paper I, Figure 6g). To our knowledge no previous studies have reported a 
correlation between WEE1 and IGF1R mRNA expression in CMM tumors (p<0.001, 
r=0.74). 
In summary we show that the combination treatment of afatinib and crizotinib is highly 
efficacious compared to single treatment, plausibly due to the concurrent inhibition of 
multiple RTKs preventing upregulation of alternate salvage pathways sue to receptor 
crosstalk. In vitro, the afatinib and crizotinib combination treatment ablated cell proliferation, 
cell viability, invasion, migration and induced apoptosis. Treating a A375 xenografted mouse 
model with the afatinib and crizotinib combination treatment abrogated tumor growth rate as 
compared to vehicle or single treatments, thus indicating that this combination is effective in 
vivo and also did not cause any severe toxicities at the tested concentrations. Lastly we 
showed that WEE1 and IGF1R, two non-canonical targets of the drugs are inhibited with the 
combination treatment and to a lesser extent with single treatments. Our study suggests that 
42 
 
IGF1R and WEE1 are potential targets of afatinib and crizotinib combination. Ongoing 
clinical trials using WEE1 inhibitor MK-1775  are being conducted for solid tumors to 
evaluate the clinical efficacy of WEE1 inhibition (Kuzu, Gowda et al. 2018). Targeting 
IGF1R in phase I/ II trials led to SD in only 38% of patients with recurrent platinum sensitive 
ovarian tumors. Therefore it is imperative to identify predictive biomarkers for IGF1R 
mediated therapies to select subset of patients who could benefit from such therapies 
(Werner, Sarfstein et al. 2019).   
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4.2 Paper II:  Downregulation of the insulin/MTOR signaling pathway by afatinib and 
crizotinib combination treatment confers broad cytotoxic effects in cutaneous 
malignant melanoma 
 
Targeted therapies have often been deemed as promiscuous because they have several off-
target effects. The main known targets for afatinib are RTKs EGFR, ERBB2, ERBB4 and 
those for crizotinib are MET/ALK/ROS1. However, based on the results from paper I, we 
postulate that there are additional key molecular targets beyond these and in addition to 
WEE1 and IGF1R that could play a role in mediating sensitivity to the afatinib and crizotinib 
combination therapy. Identification of these novel targets could be of clinical benefit. 
 
4.2.1 Results: In this study, we sought to elucidate molecular mechanisms behind the broad 
cytotoxic effects of afatinib and crizotinib in combination. Herein, we employed three 
different approaches: Phosphoproteome and whole proteome based profiling using mass-
spectophotometry (MS), Reverse Phase Protein Array (RPPA) and pRTK array to determine 
changes occuring in CMM cells and xenograft tissues (from model used in Paper I) at the 
protein level upon treatment with single or combination treatment. For the MS analysis, we 
treated A375 (BRAF mutant) and SkMEl2 (NRAS mutant) for 3 h to capture the early and 
thereby most likely direct drug targets. Our results indicated that DNA damage / ribosome 
processing/ mTOR and Insulin signaling pathways were significantly deregulated (p<0.05, 
linear fold change=1.5). Total LAMTOR 5, pRPTOR (S859) and pRB1 (S795) for both cell 
lines while pIRS-2 (S391,560,577,679, 915), total LAMTOR 1 and pCDC25B (K334, S375) 
specific for A375 and pRPS6 (S235,236,240) for SkMel2 stood out as candidate targets that 
were significantly de-regulated (Paper II, Figure 1b). RPPA analysis was performed where 
A375, A375VR4, SkMel2, ESTDAB102 and ESTDAB105 were treated with drugs for 3 h 
(to capture early effects) and 24 h (to capture those proteins that were differentially expressed 
when subjected to cellular stress).  In accordance with our analysis by MS, we found that 
PI3K/AKT and mTOR pathways were significantly deregulated. We also showed that the 
combination treatment mediated downregulation of p-RPS6 in all five cell lines (Paper II, 
Figure 1d-e, Supplementary figure S4). IRS-2 in the insulin signalling was among the top 
down-regulated candidates in A375 phosphoproteomic analysis when comparing DMSO vs 
combo. However, since this protein was absent in the RPPA panel, we checked for another 
insulin receptor substrate, IRS-1, instead and observed a slight overall decrease of total IRS-
1 in protein expression at 24 h post combination treatment in SkMel2 and A375VR4 (Paper 
II, Figure 1e). Pathway analysis performed on results obtained from a similar conducted 
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RPPA analysis using tumor tissue lysates from A375 xenograft mouse model further 
corroborated the significant downregulation of insulin and PI3K/AKT pathways with the 
combination treatment (Paper II, Figure 2a-b). Due to high FDR rates for the in vivo RPPA 
results, we used immunoflourescence to validate these data. Our results indicated that a 
greater loss of IRS-1 nuclear signal in the combination arm compared to single treatments or 
vehicle. We also confirmed our in vitro observations of the combination treatment mediated 
loss of pRPS6KB1, total RPS6KB1 and pRPS6. In vitro validations using CMM cell lines 
treated for 3 h further corroborated our results (Paper II, Figure 2c-e, Supplementary Figure 
S5). Notably we also showed that induced resistance towards the combination could be 
reversed by a ‘drug holiday’  (in our study, the holiday phase was for 2 weeks). RPPA 
analysis performed on drug sensitive A375 and resistant A375 sublines also showed that 
PMEL/ gp100 (significant) and PI3K-p85 (not significant) was upregulated in combination 
resistant sublines compared to afatinib resistant,crizotinib resistant or drug sensitive sublines 
(Paper II, Figure 3, Supplementary Figure S6). We showed that growth of CMM cells 
cultured in CAF conditioned media caused upregulation of p-AKT in CMM cells which could 
partly attribute to the increase in cell growth observed in only the vemurafenib resistant cell 
line A375VR4. However, no altered protein expression was observed in IRS-1, RPS6KB1 
and RPS6 under a similar setting (Paper II, Figure 4, Supplementary figure S9). Moreover, 
when analyzing tumor samples from CMM patients with stage I-IV disease, we observed 
differential staining and localization patterns of IRS-1, RPS6KB1 and RPS6. Our results 
indicated that IRS-1 was predominantly localized in the nucleus in Stage III/IV (73%) CMM 
compared to Stage I/II (28%). We also observed that RPS6KB1 expression was strong in 
Stage III/IV (53%) disease compared to Stage I/II (4%) (Paper II, Figure 5). In addition, we 
analyzed data from TCGA and found that patients with NRAS mutant CMM had higher IRS-
1 compared to patients with BRAF mutant CMM (Figure 12, Paper II, Figure 6a). Analysis 
of gene expression data from previously published studies indicated that high IRS-1 was 
associated with poorer OS for CMM patients on immunotherapy (Figure 14, Paper II, Figure 
6b). Finally, we demonstrated that IRS-1 and RPS6KB1 was commonly heterogeneously 
expressed in the CMM tumors. Additionally we observed a differential pattern of protein 
cellular localization on comparing treatment naïve patients to those who were previous 






Figure 14: (a) Analysis of TCGA data showing that IRS-1 expression is higher in NRAS mutant CMM 
compared to BRAF mutant CMM at both mRNA and protein levels. (b) High IRS-1 is associated with 
shorter OS (Riaz, Havel et al. 2017). (c) IRS-1 and RPS6KB1 is heterogenously expressed in CMM 
clinical samples 
 
4.2.2 Discussion: This exploratory study focused on identifying molecular targets that 
contribute to the broad cytotoxic response of afatinib and crizotinib combination therapy. By 
multiple proteomic approaches, we found that the combination of afatinib and crizotinib 
primarily de-regulated the expression of proteins belonging to the PI3K/AKT, mTOR, 
Insulin signaling, and DNA repair pathways. Herein we identified IRS-1 (known substrate 
molecule for IR/IGF1R), pAKT, pRPS6KB1 and pRPS6 as potential key targets contributing 
towards the combination treatment mediated effects. Moreover, we suggest that upregulation 
of PMEL/gp100 and PI3K-p85 might be important factors in mediating resistance to this 









IRS-1 has been previously shown to be upregulated in vemurafenib resistant CMM cells 
derived from patients and it has been reported that therapeutic destruction of the insulin 
receptor (IR) evoked death in melanoma cells. This concept was further validated in vivo 
where the authors presented that treating a mouse model xenografted with A375 cells using 
the compounds targeting IR/IGF1R/IRS abrogated tumor growth  (Reuveni, Flashner-
Abramson et al. 2013). Herein, we showed that the afatinib and crizotinib combination 
treatment downregulate IRS-1 signal in CMM cell lines (3/7) and in vivo (Paper II, Figure 
2c-e, Supplementary Figure S4-S5). mTOR pathway has been studied extensively and several 
reports have highlighted the role of mTOR in melanoma pathogenesis. mTOR activation has 
previously been reported in a majority of melanoma clinical samples  (Karbowniczek, Spittle 
et al. 2008). Moreover, it has been shown that everolimus, a mTOR inhibitor reduces 
melanoma cell invasiveness (Ciolczyk-Wierzbicka, Gil et al. 2020). Previous publications 
have also suggested combining MAPK and mTOR inhibitors as an effective way to inhibit 
CMM growth, invasion and induce cell death (Lasithiotakis, Sinnberg et al. 2008). Moreover 
it has also been shown that cross resistance to BRAF and MEK inhibitors in CMM can be 
overcome by targeting AKT/mTOR pathway (Atefi, von Euw et al. 2011). RPS6KB1 and 
RPS6, other candidates identified in our study, are key players of the mTOR pathway. 
Abberant phosphorylation of RPS6 has been shown to confer resistance to MAPKi in BRAF 
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mutant CMM (Gao, Wang et al. 2019). Furthermore, RPS6KB1 hyperphosphorylation has 
been associated with poor prognosis in NSCLC patients (Chen, Yang et al. 2017). Our reults 
were also in accordance with these observations as we showed that RPS6KB1 and RPS6 
expression was higher in stage III/IV tumors compared to stage I/II (Paper II, Figure 5). 
Using immunoblotting, RPPA and immunoflourscence, we were able to show that both 
activated and total forms of RPS6KB1 and RPS6 were downregulated upon treatment with 
the combination of afatinib and crizotinib.  
When analyzing tumor samples (n=65) from patients with advanced melanoma (Stage 
III/IV),we have also observed that patients who were treated with radiation, chemotherapy, 
targeted therapy (MAPKi and RTK inhibitors) or  checkpoint inhibitors before taking the 
biopsy had lower nuclear IRS-1 signal than patients who were treatment naïve before biopsy 
was taken (33% vs 50%). This suggests that treatments plausibly downregulate nuclear signal 
which could be therapeutically relevant. In our study, we also notably see that the 
combination is able to reduce nuclear IRS-1 signal.  
Importantly, we also show that induced resistance towards the combination is reversible by 
stopping treatment for a short duration. Our results suggest PMEL/gp-100 and PI3K-p85 as 
mediators of resistance to the combination as both were found upregulated in afatinib and 
crizotinib combination resistant cells (Paper II, Figure 3). PMEL has been previously shown 
to be overexpressed in malignant cells and has been used as a therapeutic target for refractory 
tumors (Park, Talukder et al. 2017). gp-100 peptide vaccine is also under clinical trials as 
monotherapy or in combination with other immunotherapies as a possible treatment option 
for CMM (Domingues, Lopes et al. 2018). Upregulated expression of p85 and p110-alpha 
subunits of PI3K have been previously described in melanoma and therefore PI3K has been 
considered as a good therapeutic target (Aziz, Davies et al. 2009). 
In summary we show that downregulation of IRS-1, RPS6KB1 and RPS6 could plausibly 
contribute to the additive effects of the combination treatment. Moreover, we show that the 
combination treatment  downregulates AKT signaling which may further contribute towards 
the cytotoxic effects of this combination therapy. We highlight PMEL/gp-100 and PI3K-p85 
as associated with induced resistance towards the combination treatment which we have 







4.3 Paper III: AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in 
cutaneous malignant melanoma  
 
ROS is generated as by-products in different cellular compartments as a result of various 
enzymatic reactions. ROS can have deleterious effects on DNA as it can induce DNA damage 
and therefore compromise genomic stability. To counteract this process, cells are armoured 
with several defense mechanisms collectively forming the DNA repair system. One player 
integral to the DNA repair process is MTH1 which hydrolyzes harmful oxidative stress 
induced 8-oxo-dGTP, thus sanitizing the DNA pool. Several studies have shown that MTH1 
is often upregulated in different cancer types, thus making it a plausible therapeutic target of 
choice.  
 
4.3.1 Results: In this study we report that CMM cells are sensitive to the MTH1 inhbitor 
TH1579 independent of BRAF/NRAS mutation status, here shown as a loss in cell viability 
by drug treatment for 72 h in 2D (Paper III, Figure 1B) and 3D (Paper III, Figure 1C). 
Moreover, by using an orthotopic zebrafish embryo model, we also showed that the cytotoxic 
effects of TH1579 were valid in vivo. Staining of Ki67 in tissues obtained from these treated 
embryos indicated a loss in proliferation after treatment (Paper III, Figure 1F-H).  To 
recapitulate molecular intra and inter tumor heterogeneity, which is often seen in CMM with 
presence of resistant clones which under drug pressure have a growth advantage, we mimiced 
this in an in vitro model. We co-cultured one BRAF mutant BRAFi sensitive cell line and the 
BRAFi resistant subline with WT cells in one set and two NRAS mutant cell lines with a WT 
cell line as another set and analyzed cell death and cell viability loss. We showed that in such 
a setting, TH1579 was most potent at killing CMM cells as compared to the other drugs 
(BRAFi for BRAF mutant cells and MEKi for NRAS mutant and BRAF/ NRAS WT cells) that 
are clinically used for CMM. We also used 3D spheroid co-culture model to validate our 
findings. Moreover, using time-lapse microscopy, we showed that TH1579 caused G2/M cell 
cycle arrest in BRAF mutant CMM cells (Figure 16, Paper III, Figure 2, Supplementary 
figure S2). Moreover cell cycle analysis experiments also showed that in BRAF/NRAS WT 
CMM cells ESTDAB 105 a G2/M cell cycle arrest was induced after TH1579 treatment. 
Concomitant with these observations, we also saw reduced colony formation in ESTDAB105 




Figure 16: (A) Experimental set up for co-culture. (B,C) Representative images and quantification of 
viable cells from BRAF set and NRAS set after treatment at indicated time points using time lapse 
imaging. (D) Results from single and co-culture exprements after treatment using FACS. (E,F) 
Representative images of spheroids after single or co-culture and treatment with TH1579. (G) FACS 
results for CMM cells as single cultures treated with 0.9µM TH1579 for 48 h. (H,I,J). Representative 
images and quantification of time lapse imaging showing mitotic lag in TH1579 treated cells when 




Next we demonstrated that TH1579 treatment induced ROS in CMM cells and that this ROS 
induction correlated significantly with percentage of apoptotic cells (p<0.05, r=0.95). Using 
immunoblotting and a modified comet assay, we were able to observe that the TH1579 
treatment induced DNA damage (Paper III, Figure 3, Supplementary figure S3). To deduce 
the importance of MTH1 in TH1579 mediated cytotoxicity, by using cell lines transfected 
with a doxycycline inducable shMTH1 plasmid, we showed that in all cell lines tested except 
in the A375 vemurafenib resistant subline A375VR4, silencing of MTH1 alone significantly 
caused a reduction in cell proliferation (p<0.01) (here assessed by loss of colonies formed) 
and elevated cell death. Although shMTH1 did not cause any obvious cytotoxic effects on 
A375VR4, we were able to observe induction of DNA damage marker p-H2AX upon 
knocking down MTH1. Downregulating MTH1 in A375VR4 did not alter time spent during 
mitosis. (Paper III, Figure 4). To elucidate the molecular mechanisms behind TH1579 
mediated effects, we performed immunoblotting after treatment with TH1579 to look at the 
changes in protein expression of key RTKs and downstream effectors previously associated 
with MAPKi resistance. Immunoblotting results indicated that TH1579 treatment reduced 
AXL, IGF1R, EPHA2 and pAKT protein levels. We also observed that cells with high AXL 
mRNA were more sensitive to TH1579 (Paper III, Figure 5C). Therefore, we over-expressed 
AXL in CMM cells with low endogenous AXL levels and found that we triggered an increase 
in sensitivity to TH1579 in these cells (Paper III, Figure 5D-E). To find a mechanistic 
explanation as to why A375VR4 was not responding the same way to MTH1 silencing as the 
other CMM cells, we also looked at alternative possibilities. A previous study on lung cancer 
reported that increased interaction of CAV-1 and MTH1 by mutant K-RAS resulted in 
inhibition in MTH1 activity (Volonte, Vyas et al. 2018). Previous work from our lab has 
shown that A375VR4 has higher expression of CAV-1. To deduce if CAV-1 mediates lack 
of sensitivity upon MTH1 knockdown in A375VR4 we checked if TH1579 had any effects 
on CAV-1 protein levels.  We demonstrated that TH1579 downregulated CAV-1 and we also 
found that CAV-1 and MTH1 existed in close proximity to each other in A375VR4 cells, 
shown by isPLA (Paper III, Figure 5K-L). We couldn’t however determine any physical 
interaction between CAV-1 and MTH1 (Paper III, Supplementary figure S8). We showed 
that TH1579 downregulated CAV-1 signal in A375VR4 (Paper III, Figure 5M) and AXL in 
both A375VR4 and SkMel2 in vivo  (Paper III, Supplementary figure S5). Lastly, we 
observed that combination treatment of TH1579 together with BRAFi further invoked loss 
of cell viability compared to single treatment in BRAF mutant cells, including BRAFi 
resistant cells (Figure 17, Paper III, Figure 6A, Supplementary figure S10). We further 
validated the combination effects using TH1579 and vemurafenib and showed that the 
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combination treatment significantly triggered higher cell death and ROS induction in BRAF 
mutant cells than single agents (Figure 17, Paper III, Figure 6B-C). We also confirmed that 
this combination effect was true in vivo. Lastly, we showed that in A375VR4, the 
combination treatment effectively downregulated both CAV-1 and pAKT expression (Paper 
III, Figure 6F-G).  
 
Figure 17: (A) Cell viability assay showing A375 and A375VR4 cells treated with single and 
combination drugs for 72 h. (B) Apoptosis assay showing effects on cell death in A375 and A375VR4 
cells treated with single and combination drugs for 48 h. (C) Assay showing ROS induction in A375V4 
with single and combination drugs after 3 h. (D-E) Representative image and quantification showing 
effects of tumor size in vivo after single and combination treatments for 72 h. (F-G) Immunoblotting 
showing effects on AXL, CAV-1 and AKT after drug treatment for 48 h.(Das, Gad et al. 2020) 
 
4.3.2 Discussion: Several studies have emphasized on ROS being a critical mediator in the 
etiology of human diseases. Mutations induced as a result of oxidative damage to cellular 
DNA by ROS have been shown to contribute towards initiation and progression of cancer 
(Malins, Polissar et al. 1996, Behrend, Henderson et al. 2003, Waris and Ahsan 2006). 
Studies have linked the role of ROS in several steps during melanoma onset and progression 
(Wittgen and van Kempen 2007), thereby implying that targeting ROS in melanoma could 
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be therapeutically beneficial. To escape the deleterious effects of ROS, cancer cells often 
overactivate DNA repair mechanisms that promote mitosis to avoid oxidative DNA damage 
(Gad, Koolmeister et al. 2014, Gad, Mortusewicz et al. 2019). For example, overexpression 
of DNA repair protein MTH1 has been observed in many tumor types (Kennedy, Cueto et al. 
1998, Pudelko, Rouhi et al. 2017, Wang, Liu et al. 2017).   
In this study, we have investigated the applicability of MTH1 inhibitor TH1579 as a novel 
therapeutic potential in CMM. Since MTH1 has been shown to promote mitosis to evade 
DNA damage (Gad, Mortusewicz et al. 2019), we investigated and found that inducing 
mitotic arrest was one of the mechanisms by which the inhibitor TH1579 worked in our cell 
line panel. A study by Wang et al showed that ROS levels present in melanoma cells dictated 
their response towards TH588- an analog of TH1579 (Wang, Jin et al. 2016). As indicated in 
a previous study TH588 was also used to demonstrate antitumor effects in neuroendocrine 
cells (Aristizabal Prada, Orth et al. 2017). Herein, we showed that TH1579 treatment induced 
DNA damage, loss of proliferation and viability and induced apoptosis (Paper III, Figure 1-
3) in CMM cells. Since the direct role of MTH1 in cancer therapy has been debated where 
some studies have highlighted MTH1 to be an important  target in cancer (Koketsu, Watanabe 
et al. 2004, Gad, Koolmeister et al. 2014, Brautigam, Pudelko et al. 2016, Warpman 
Berglund, Sanjiv et al. 2016, Aristizabal Prada, Orth et al. 2017, Pudelko, Rouhi et al. 2017, 
Wang, Liu et al. 2017, Einarsdottir, Karlsson et al. 2018, Zhou, Ma et al. 2019), whereas 
other studies have shown inhibition of MTH1 to be non-toxic to cancer cells (Takagi, 
Setoyama et al. 2012, Kawamura, Kawatani et al. 2016), we knocked down MTH1 using 
shRNA to evaluate the cytotoxic effects. Our results showed that except for BRAF mutant 
vemurafenib resistant cell line A375VR4, all other cell lines investigated showed loss of 
proliferative cells and induced cell death upon MTH1 knockdown (Paper III, Figure 4). In 
this study, we also found that AXL and CAV-1 play a role in mediating sensitivity towards 
TH1579. The role of AXL and CAV-1 in cancer development and therapy resistance has 
been well established (Zhang, Lee et al. 2012, Muller, Krijgsman et al. 2014, Wang, Wang 
et al. 2015, Balaji, Vijayaraghavan et al. 2017, Ketteler and Klein 2018). Therefore, 
downregulating AXL and CAV-1 expression may be one of the plausible mechanisms of 
action behind TH1579 mediated cytotoxic effects (Paper III, Figure 5, Supplementary figure 
S5 and S8). Several recently reported studies have shown that combining different drugs with 
MTH1 inhibitor leads to a more effective amelioration of cancer cells (Einarsdottir, Karlsson 
et al. 2018, Ikejiri, Honma et al. 2018). We have also shown that combining BRAFi with 
TH1579 resulted in further sensitization compared with using either inhibitor alone in BRAF 
mutant CMM cells (Paper III, Figure 6, Supplementary figure S10).   
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In summary we show that TH1579 is cytotoxic for all melanoma cells independent of 
BRAF/NRAS mutation status. TH1579 treatment induces ROS in CMM cells. We also show 
that cells with BRAFi resistant cell line A375VR4 expressing high AXL and CAV-1 as well 
NRAS mutant cell line SkMEl2 expressing high AXL levels are sensitive to TH1579. 
Overexpression of AXL in AXL low cells further sensitizes them to TH1579 treatment 
(Figure 18, Paper III, Figure 7). Furthermore, AXL upregulation which has been associated 
with BRAFi resistance was downregulated by MTH1 alone and in combination treatment 
with BRAFi.  
 
 










4.4 Paper IV: Co-expression of MTH1 and PMS2 is associated with shorter 
progression-free survival after immunotherapy in cutaneous malignant melanoma 
 
Genomic instability is a known hallmark of cancer and it has been shown previously that 
mutation burden in tumors can be an important predictive biomarker for response to immune 
checkpoint inhibitors (ICI). Patients with high tumor mutational burden (TMB) are predicted 
to respond better to ICI. Melanoma has high TMB and is considered immunologically ‘hot’ 
as the tumors generally comprise of an abundance of tumor infiltrating lymphocytes. 
However, many CMM patients do not respond to ICI.   
4.4.1 Results: In this study we have analyzed data from TCGA and have shown that patients 
who express high mRNA levels of MTH1 and PMS2 have significantly (p<0.05) shorter 
disease-free survival (DFS) and OS (Paper IV, Figure 1b). Moreover, we found that PMS2 
and MTH1 protein was co-expressed in patients with stage III/IV disease in comparison to 
those with stage I/II disease or normal skin (Paper IV, Fig 1c-d). We also observed that in 
stage III/IV tumors, the distribution of MTH1 localization was more common (~74%) in the 
nucleus as compared to Stage I/II tumors (~32%) (Paper IV, Supplementary figure S1). 
Furthermore, we have highlighted that co-expression of MTH1 and PMS2 is associated with 
a worse PFS in CMM patients who have been treated with ICI. However, when sub-
categorizing these patients based on response to therapy using data from a previously 
published study, we were only able to see that median mRNA expression of MTH1 was 
higher (not significant) in patients with progressive disease (PD) as compared to partial 




Figure 19: (a) Kaplan Meier curves showing PFS of CMM patients treated with immunotherapy with 
MTH1 high or low, PMS2 high or low or MTH1 and PMS2 high or low. (b) Differences in mRNA 
expression levels of MTH1 and PMS2 in the same cohort of patients but grouped as those with PFS 
< 6 months or > 6 months. (c) Difference in MTH1 and PMS2 mRNA levels in patients grouped as 
CR, PR or PD (dataset used from (Hugo, Zaretsky et al. 2016))  
 
Next we showed that patients who had been treated with targeted or immunotherapy at 
relapse co-expressed MTH1 and PMS2 protein and also had elevated expression of the two 
proteins (Paper IV, Figure 3). Finally, we treated a selected set of established and short-term 
patient derived CMM cells with MTH1 inhibitor TH1579 and observed an induction of DNA 
damage (here seen by elevated levels of p-H2AX),downregulation of PMS2 protein, loss of 
cell viability and significantly (p<0.05) reduced tumor spheroid size after treatment with 
TH1579. FACS analysis of tumor cells treated with TH1579 also showed induction of 
apoptotic cell death (Paper IV, Figure 4a-f, Paper III, Figure 3G). Finally we showed that 
by silencing MTH1 and PMS2 concurrently, we could invoke a significant induction in 
apoptotic cell death as compared to silencing either MTH1 or PMS2 alone (Paper IV, Figure 
4g).  
 
4.4.2 Discussion: In this study we have highlighted the role of DNA repair with regards to 
treatment response to clinical therapy in CMM.  As per our knowledge, this is the first study 
demonstrating that co-expression of MTH1 and PMS2 is observed in clinically advanced 
CMM tumors and that it is associated with shorter PFS in patients treated with 
immunotherapy.  
Abberant genetic alterations, especially gene amplifications of chromosome 7 has been 
associated to be a marker of metastatic melanoma (Bastian, LeBoit et al. 1998, Udart, Utikal 
et al. 2001). Both MTH1 and PMS2 are located on chromosome 7. Although no previous 
studies have shown amplifications in MTH1 and PMS2 in association with cancer, in this 
study we have shown correlation between PMS2 and MTH1 CNV (Paper IV, Figure 1a). 
We also found a similar correlation at the mRNA level (Paper IV, Figure 1c-e). Several 
studies have demonstrated an upregulation of MTH1 expression in several cancers including 
CMM (Wang, Liu et al. 2017). However, the role of PMS2 is relatively unknown. Previous 
data indicates that PMS2 deficiency increases the incidence of several cancers like breast, 
stomach, prostate (Kasela, Nystrom et al. 2019) on one hand, whereas another study has 
shown that an increase in PMS2 expression is associated with prostate tumor aggressiveness 
(Wilczak, Rashed et al. 2017). Yet another study in ovarian cancer evaluating the prognostic 
value of DNA repair proteins for patients treated with platinum based chemotherapy showed 
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that those patients with higher PMS2 had a favorable OS (Zhao, Li et al. 2018). In this study 
we have shown that patients treated with immunotherapy who have high PMS2 and MTH1 
mRNA expression have a significantly worse PFS (p<0.001) (Figure 19,Paper II, Figure 
2a). Furthermore,  patients treated with targeted or immunotherapy show a increased 
expression of PMS2 and MTH1 as well as co-expression of the two proteins at relapse (Paper 
III, Figure 3). These data indicate  that for CMM, co-expression of MTH1 and PMS2 has a 
poor prognostic value. Therefore we propose that co-silencing of MTH1 and PMS2 could be 
a better therapeutic strategy since concurrent silencing of both these proteins led to increased 
cytotoxicity in CMM short-term patient derived cells (Paper IV, Figure 4). 
In summary we show that MTH1 and PMS2 is co-expressed in advanced CMM tumors 
(Stage III/IV) and in refractory tumors. We therefore elucidate that though patients may 
initially respond to therapy, those who harbor clones of MTH1 and PMS2 positive tumor 
cells have risks of relapse (Figure 20). However, to which extent these two proteins play a 
role in attributing towards relapse cannot be deduced from this study. Moreover we show 
that patient derived CMM cells (including cells from a relapsed patient) are sensitive to 
TH1579 (Karonudib). TH1579 was able to ablate growth of tumor spheroids established from 
patients undergoing immunotherapy. TH1579 is currently in phase 1 clnical trials for solid 
and haematological malignancies. Based on our findings we suggest that combining 
immunotherapy with TH1579 might be an attractive option for improving therapy efficacy 
in CMM treatment.   
  
 
Figure 20: Schematic illustration showing association of MTH1 and PMS2 expression to CMM 
disease stage and therapy response
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5. CONCLUSIONS AND FUTURE PRESPECTIVES 
 
Understanding the molecular mechanisms behind melanoma onset and pathogenesis has been 
fundamental when developing new therapeutic strategies for CMM treatment. Although 
treatment of advanced CMM with immunotherapy and targeted therapy has significantly 
improved the overall survival, there are still patients who do not respond to either treatments, 
making it an unmet need to develop further therapy options for such patients. Moreover, a 
deeper understanding of the biology of the disease and response to therapies is warranted to 
identify subgroups who would have long-term benefit of the current therapies and also to be 
able to further develop alternative treatment options. The objective of this thesis was to 
uncover novel therapeutic alternatives for CMM and to unravel new druggable molecular 
targets for an improved clinical efficacy.  
 
In paper I we elucidated the therapeutic potential of afatinib and crizotinib as a combination 
treatment strategy for CMM. We showed that the novel combination treatment caused loss 
of cell viability, cell proliferation, migration, invasion and induced cell death in melanoma 
cells. In line with our in vitro studies, we were also able to show that the combination 
treatment significantly abrogated tumor growth rate in a A375 xenograft mouse model 
without any severe toxic effects. Lastly, we showed that downregulation of WEE1 and 
IGF1R expression was associated with the broad phenotypic effects of the combination 
treatment.  Future studies are warranted to combine WEE1 and or IGF1R inhibitors either in 
combination with each other, with MAPKi or with afatinib and crizotinib to see if these 
combinations can elicit a further cytotoxic response in CMM cells. WEE1 and IGF1R 
expression in association to therapy response also needs to be further studied in CMM clinical 
samples to understand more lucidly their roles in disease relapse.  
 
In paper II we expanded our study from paper I. To do so, we performed an in depth analysis 
to unravel key molecular mediators underlying the broad phenotypic effects of afatinib and 
crizotinib in combination. We saw that PI3K/AKT, mTOR, Insulin signaling and DNA 
damage pathways were deregulated by the combination therapy. Taking into consideration 
our in vitro and in vivo data, we decided to focus on the mTOR and insulin pathways. We 
found that IRS-1, RPS6KB1 and RPS6 were among the most significantly downregulated 
proteins by combination treatment both in vitro and in vivo. Staining of these proteins in 
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CMM clinical samples showed that RPS6KB1 and RPS6 expression was higher in more 
advanced disease. We also found a discernable nuclear IRS-1 signal in ~50% of stage III/IV 
tumors compared to Stage I/II where almost no nuclear localization was observed. 
Furthermore we observed that IRS-1 mRNA expression was higher in NRAS mutant tumors 
and that higher IRS-1 expression was associated with significantly shorter OS in CMM 
patients on immunotherapy. This study provides a platform for future exploratory studies 
since we also found other proteins associated with cell cycle, DNA damage and metabolism 
which we infer as interesting candidates that have in part already been shown to play a role 
in melanoma etiology. A better understanding behind the association of these candidates and 
the their role in different stages of melanoma would help develop novel targeted therapies 
which could provide clinical benefit. 
 
In paper III we investigated the therapeutic potential of MTH1 inhibitor TH1579 in CMM. 
We found that CMM cells were sensitive to TH1579 independent of BRAF/NRAS mutation 
status. TH1579 treatment elicited DNA damage, ROS accumulation, mitotic arrest and cell 
death in CMM cells. AXL high CMM cells were particularly sensitive to TH1579 and by 
overexpressing AXL in AXL low cell lines, we could sensitize them to TH1579 treatment. 
We also observed that in vemurafenib resistant cell line A375VR4, CAV-1 played a role in 
mediating sensitivity to the inhibitor. Lastly we also saw that by combining BRAF inhibitors 
with TH1579, we could enhance the sensitivity of BRAF mutant CMM cells. This observation 
was made both in vitro and in an orthotopic zebrafish model system. This study advocates 
combining BRAFi with TH1579, thereby providing an alternative therapy regime for 
refractory tumors where resistance to BRAFi has developed. Further studies are required to 
understand how AXL and CAV-1 may play a role in TH1579 mediated cytotoxic effects and 
whether combining AXL inhibitors with TH1579 might provide opportunities for enhanced 
therapeutic efficacy.  
  
In paper IV we studied the significance of  MTH1 and PMS2 in relation to therapy response 
and disease stage. We found that patients who received immunotherapy with concomitantly 
high PMS2 and MTH1 mRNA expression in their pre-treatment tumors had a significantly 
shorter PFS. We observed that refractory tumors comprised of clones of cells that co-
expressed MTH1 and PMS2. Moreover we also saw that CMM cells derived from patients 
administered with immunotherapy were sensitive to MTH1 inhibitor TH1579 when cultured 
as spheroid models. Lastly we found that co-silencing MTH1 and PMS2 evoked cell death 
more significantly than when either MTH1 or PMS2 was silenced alone. In order to validate 
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this hypothesis and hopefully bring it into clinical practice, validation studies with larger 




























6. THESIS SUMMARY: A POPULAR SCIENCE VERSION  
 
Employing novel treatment approaches to combat the deadliest skin cancer 
Melanoma is the deadliest form of skin cancer with an increasing incidence rate worldwide. 
It is easier to cure melanoma if detected early, but once it has advanced, it could be a serious 
problem to treat. Currently targeted therapy and immunotherapy, activating the immune 
system, are employed which have significantly improved the survival for many patients 
with advanced melanoma. However, only a subgroup of these patients has sustained benefit 
of the treatment. The majority of the patients do not respond or have a relapsed disease 
during treatment or upon treatment cessation because they are or become unresponsive to 
the treatment. A number of studies are ongoing to find biomarkers to be able to identify 
patients who are likely to have long-term benefit from the current treatments as well as 
finding novel treatments for the subgroups who do not respond or have short-term benefit 
(personalized medicine). However, we still have a long way to go before personalized 
treatment becomes a reality. My thesis therefore focuses on finding alternative therapy 
options for melanoma patients. 
We have explored broadly two novel treatment strategies with the aim to find effective 
novel treatments for melanoma. For the first approach, we have tested two drugs in 
combination (afatinib and crizotinib), which have been clinically approved for lung cancer 
but not for melanoma treatment. In the other approach we have investigated a drug TH1579 
(karonudib) alone or in combination with drugs clinically approved for BRAF mutant 
melanoma. TH1579 is under investigation in clinical studies to assess the tolerance in 
patients with different types of tumors. We show that afatinib and crizotinib in combination 
or TH1579 alone or in combination with clinically approved drugs used to treat melanoma 
patients is able to provide an anti-tumor effect that not only manages to reduce the tumor 
growth, but is also able to restrict the spread of the tumor, a major challenge in melanoma. 
These therapeutic strategies are also ultimately able to kill the cancer cells. 
The effects of TH1579 and the afatinib and crizotinib drug combination were also studied 
in animal models. We found that the melanoma cells were successfully killed by the drugs, 
supporting our proof of concept. We here suggest potential novel targeted therapeutic 
strategies for patients with melanoma to study further with a hope that they would be 
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